Master Alliance Provisions Guide (MAPGuide)

Search Results For:

  • Search results for:
    • CEPI
(Click + to show provisions)
Agreement title
Effective date
Partner type
Technology
Development stage

				GHIAA2019\MapguideSearch Object
(
    [search_parameters] => Array
        (
            [qs] => CEPI
        )

    [filters] => Array
        (
            [text_search] => CEPI
        )

    [child_filters] => Array
        (
        )

    [agreement_args] => 
    [provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [post__in] => Array
                (
                    [0] => 12021
                    [1] => 12007
                    [2] => 12006
                    [3] => 12005
                    [4] => 12004
                    [5] => 11999
                    [6] => 11998
                    [7] => 11931
                    [8] => 11930
                    [9] => 11928
                    [10] => 11927
                    [11] => 11926
                    [12] => 11925
                    [13] => 11924
                    [14] => 11920
                    [15] => 11923
                    [16] => 11917
                    [17] => 12009
                    [18] => 11918
                    [19] => 12008
                    [20] => 8491
                    [21] => 8490
                    [22] => 8489
                    [23] => 8488
                    [24] => 8487
                    [25] => 8486
                    [26] => 8485
                    [27] => 8484
                    [28] => 8482
                    [29] => 8481
                    [30] => 8480
                    [31] => 8479
                    [32] => 8469
                    [33] => 8468
                    [34] => 8467
                    [35] => 8462
                    [36] => 8461
                    [37] => 8314
                    [38] => 8313
                    [39] => 8312
                    [40] => 8311
                    [41] => 8192
                    [42] => 8191
                    [43] => 8190
                    [44] => 8157
                    [45] => 8152
                    [46] => 8151
                    [47] => 8150
                    [48] => 8143
                    [49] => 8142
                    [50] => 8131
                    [51] => 8130
                    [52] => 8129
                    [53] => 8051
                    [54] => 5782
                    [55] => 5653
                    [56] => 5652
                    [57] => 5427
                    [58] => 4580
                    [59] => 4205
                    [60] => 4204
                    [61] => 4201
                    [62] => 4200
                    [63] => 4141
                    [64] => 4140
                    [65] => 4139
                    [66] => 4138
                    [67] => 4137
                    [68] => 4136
                    [69] => 4135
                    [70] => 4134
                    [71] => 4133
                    [72] => 4131
                    [73] => 4130
                    [74] => 4129
                    [75] => 4128
                    [76] => 3757
                    [77] => 3756
                    [78] => 3755
                    [79] => 3754
                    [80] => 3753
                    [81] => 3751
                    [82] => 3749
                    [83] => 3748
                    [84] => 3747
                    [85] => 3746
                    [86] => 3744
                    [87] => 3743
                    [88] => 3736
                    [89] => 3726
                    [90] => 3725
                    [91] => 3724
                    [92] => 3722
                    [93] => 3493
                    [94] => 3344
                    [95] => 3343
                    [96] => 3342
                    [97] => 3341
                    [98] => 3339
                    [99] => 3338
                    [100] => 3336
                    [101] => 3331
                    [102] => 3329
                    [103] => 3327
                    [104] => 3326
                    [105] => 3323
                    [106] => 3321
                    [107] => 3318
                    [108] => 3316
                    [109] => 3315
                    [110] => 2909
                    [111] => 2908
                    [112] => 2907
                    [113] => 2893
                    [114] => 2892
                    [115] => 2890
                    [116] => 2889
                    [117] => 2885
                    [118] => 1221
                    [119] => 1205
                    [120] => 1204
                    [121] => 1203
                    [122] => 1202
                    [123] => 1159
                    [124] => 996
                    [125] => 12021
                    [126] => 12007
                    [127] => 12006
                    [128] => 12005
                    [129] => 12004
                    [130] => 11999
                    [131] => 11998
                    [132] => 11931
                    [133] => 11930
                    [134] => 11928
                    [135] => 11927
                    [136] => 11926
                    [137] => 11925
                    [138] => 11924
                    [139] => 11920
                    [140] => 11923
                    [141] => 11922
                    [142] => 11917
                    [143] => 12009
                    [144] => 11918
                    [145] => 12008
                    [146] => 8491
                    [147] => 8490
                    [148] => 8489
                    [149] => 8488
                    [150] => 8487
                    [151] => 8486
                    [152] => 8485
                    [153] => 8484
                    [154] => 8482
                    [155] => 8481
                    [156] => 8480
                    [157] => 8479
                    [158] => 8469
                    [159] => 8468
                    [160] => 8467
                    [161] => 8462
                    [162] => 8461
                    [163] => 8314
                    [164] => 8313
                    [165] => 8312
                    [166] => 8311
                    [167] => 8192
                    [168] => 8191
                    [169] => 8190
                    [170] => 8157
                    [171] => 8152
                    [172] => 8151
                    [173] => 8150
                    [174] => 8143
                    [175] => 8142
                    [176] => 8131
                    [177] => 8130
                    [178] => 8129
                    [179] => 8051
                    [180] => 5782
                    [181] => 5653
                    [182] => 5652
                    [183] => 5427
                    [184] => 4580
                    [185] => 4205
                    [186] => 4204
                    [187] => 4201
                    [188] => 4200
                    [189] => 4141
                    [190] => 4140
                    [191] => 4139
                    [192] => 4138
                    [193] => 4137
                    [194] => 4136
                    [195] => 4135
                    [196] => 4134
                    [197] => 4133
                    [198] => 4131
                    [199] => 4130
                    [200] => 4129
                    [201] => 4128
                    [202] => 3757
                    [203] => 3756
                    [204] => 3755
                    [205] => 3754
                    [206] => 3753
                    [207] => 3751
                    [208] => 3749
                    [209] => 3748
                    [210] => 3747
                    [211] => 3746
                    [212] => 3744
                    [213] => 3743
                    [214] => 3736
                    [215] => 3726
                    [216] => 3725
                    [217] => 3724
                    [218] => 3722
                    [219] => 3493
                    [220] => 3344
                    [221] => 3343
                    [222] => 3342
                    [223] => 3341
                    [224] => 3339
                    [225] => 3338
                    [226] => 3336
                    [227] => 3331
                    [228] => 3329
                    [229] => 3327
                    [230] => 3326
                    [231] => 3323
                    [232] => 3321
                    [233] => 3318
                    [234] => 3316
                    [235] => 3315
                    [236] => 2909
                    [237] => 2908
                    [238] => 2907
                    [239] => 2893
                    [240] => 2892
                    [241] => 2890
                    [242] => 2889
                    [243] => 2885
                    [244] => 1221
                    [245] => 1205
                    [246] => 1204
                    [247] => 1203
                    [248] => 1202
                    [249] => 1159
                    [250] => 996
                    [251] => 12018
                    [252] => 5808
                    [253] => 4661
                    [254] => 4147
                    [255] => 4148
                    [256] => 4223
                    [257] => 4222
                    [258] => 4221
                    [259] => 4220
                    [260] => 4219
                    [261] => 4218
                    [262] => 4217
                    [263] => 4216
                    [264] => 4215
                    [265] => 4214
                    [266] => 4213
                    [267] => 4212
                    [268] => 4210
                    [269] => 4209
                    [270] => 4161
                    [271] => 4159
                    [272] => 4158
                    [273] => 4157
                    [274] => 4156
                    [275] => 4155
                    [276] => 4154
                    [277] => 4153
                    [278] => 4152
                    [279] => 4151
                    [280] => 4150
                    [281] => 4149
                    [282] => 4146
                    [283] => 3812
                    [284] => 3810
                    [285] => 3809
                    [286] => 3808
                    [287] => 3807
                    [288] => 3806
                    [289] => 3805
                    [290] => 3804
                    [291] => 3803
                    [292] => 3802
                    [293] => 3801
                    [294] => 3800
                    [295] => 3799
                    [296] => 3798
                    [297] => 3797
                    [298] => 3796
                )

        )

    [text_agreement_args] => Array
        (
            [post_type] => agreement
            [posts_per_page] => -1
            [s] => CEPI
        )

    [text_provision_args] => Array
        (
            [post_type] => provision_document
            [posts_per_page] => -1
            [s] => CEPI
        )

    [agreement_ids] => Array
        (
        )

    [agreement_q_rslts] => 
    [provision_q_rslts] => 
    [text_agreement_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => CEPI
                )

            [query_vars] => Array
                (
                    [post_type] => agreement
                    [posts_per_page] => -1
                    [s] => CEPI
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [orderby] => title
                    [order] => ASC
                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 1
                    [search_terms] => Array
                        (
                            [0] => CEPI
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{3a0ae59abce9aa28db367eecb9ab2ff20d90cd63276d2902cb2842f6aec6bca9}CEPI{3a0ae59abce9aa28db367eecb9ab2ff20d90cd63276d2902cb2842f6aec6bca9}'
                        )

                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT  DISTINCT wpry_posts.*
					 FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
					 WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) ) OR ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) ) )  AND ((wpry_posts.post_type = 'agreement' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
					 
					 ORDER BY wpry_posts.post_title ASC
					 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 3313
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:12:41
                            [post_date_gmt] => 2021-06-30 10:12:41
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:03
                            [post_modified_gmt] => 2021-09-15 11:58:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3313
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 4126
                            [post_author] => 5
                            [post_date] => 2022-01-28 13:33:11
                            [post_date_gmt] => 2022-01-28 13:33:11
                            [post_content] => 
                            [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-01-28 13:33:11
                            [post_modified_gmt] => 2022-01-28 13:33:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=4126
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 2882
                            [post_author] => 6
                            [post_date] => 2021-05-14 14:03:29
                            [post_date_gmt] => 2021-05-14 14:03:29
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:31
                            [post_modified_gmt] => 2021-09-15 11:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=2882
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 11914
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:19:40
                            [post_date_gmt] => 2024-09-02 09:19:40
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:19:40
                            [post_modified_gmt] => 2024-09-02 09:19:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=11914
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 3719
                            [post_author] => 5
                            [post_date] => 2021-08-23 11:02:40
                            [post_date_gmt] => 2021-08-23 11:02:40
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:58:51
                            [post_modified_gmt] => 2021-09-15 11:58:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=3719
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 8049
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:37:47
                            [post_date_gmt] => 2022-12-12 08:37:47
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2022-12-12 08:37:47
                            [post_modified_gmt] => 2022-12-12 08:37:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=agreement&p=8049
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 994
                            [post_author] => 7
                            [post_date] => 2020-05-18 19:52:27
                            [post_date_gmt] => 2020-05-18 19:52:27
                            [post_content] => 
                            [post_title] => CEPI CfP3i Vaccine Funding Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2021-09-15 11:59:18
                            [post_modified_gmt] => 2021-09-15 11:59:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=agreement&p=994
                            [menu_order] => 0
                            [post_type] => agreement
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 7
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 3313
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:12:41
                    [post_date_gmt] => 2021-06-30 10:12:41
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2021-09-15 11:58:03
                    [post_modified_gmt] => 2021-09-15 11:58:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=agreement&p=3313
                    [menu_order] => 0
                    [post_type] => agreement
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 7
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => cbc7cf2936e75bfafa1b51f04cc01845
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [text_provision_q_rslts] => WP_Query Object
        (
            [query] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => CEPI
                )

            [query_vars] => Array
                (
                    [post_type] => provision_document
                    [posts_per_page] => -1
                    [s] => CEPI
                    [error] => 
                    [m] => 
                    [p] => 0
                    [post_parent] => 
                    [subpost] => 
                    [subpost_id] => 
                    [attachment] => 
                    [attachment_id] => 0
                    [name] => 
                    [pagename] => 
                    [page_id] => 0
                    [second] => 
                    [minute] => 
                    [hour] => 
                    [day] => 0
                    [monthnum] => 0
                    [year] => 0
                    [w] => 0
                    [category_name] => 
                    [tag] => 
                    [cat] => 
                    [tag_id] => 
                    [author] => 
                    [author_name] => 
                    [feed] => 
                    [tb] => 
                    [paged] => 0
                    [meta_key] => 
                    [meta_value] => 
                    [preview] => 
                    [sentence] => 
                    [title] => 
                    [fields] => 
                    [menu_order] => 
                    [embed] => 
                    [category__in] => Array
                        (
                        )

                    [category__not_in] => Array
                        (
                        )

                    [category__and] => Array
                        (
                        )

                    [post__in] => Array
                        (
                        )

                    [post__not_in] => Array
                        (
                        )

                    [post_name__in] => Array
                        (
                        )

                    [tag__in] => Array
                        (
                        )

                    [tag__not_in] => Array
                        (
                        )

                    [tag__and] => Array
                        (
                        )

                    [tag_slug__in] => Array
                        (
                        )

                    [tag_slug__and] => Array
                        (
                        )

                    [post_parent__in] => Array
                        (
                        )

                    [post_parent__not_in] => Array
                        (
                        )

                    [author__in] => Array
                        (
                        )

                    [author__not_in] => Array
                        (
                        )

                    [search_columns] => Array
                        (
                        )

                    [suppress_filters] => 
                    [ignore_sticky_posts] => 
                    [cache_results] => 1
                    [update_post_term_cache] => 1
                    [update_menu_item_cache] => 
                    [lazy_load_term_meta] => 1
                    [update_post_meta_cache] => 1
                    [nopaging] => 1
                    [comments_per_page] => 50
                    [no_found_rows] => 
                    [search_terms_count] => 1
                    [search_terms] => Array
                        (
                            [0] => CEPI
                        )

                    [search_orderby_title] => Array
                        (
                            [0] => wpry_posts.post_title LIKE '{3a0ae59abce9aa28db367eecb9ab2ff20d90cd63276d2902cb2842f6aec6bca9}CEPI{3a0ae59abce9aa28db367eecb9ab2ff20d90cd63276d2902cb2842f6aec6bca9}'
                        )

                    [order] => DESC
                )

            [tax_query] => WP_Tax_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => AND
                    [table_aliases:protected] => Array
                        (
                        )

                    [queried_terms] => Array
                        (
                        )

                    [primary_table] => wpry_posts
                    [primary_id_column] => ID
                )

            [meta_query] => WP_Meta_Query Object
                (
                    [queries] => Array
                        (
                        )

                    [relation] => 
                    [meta_table] => 
                    [meta_id_column] => 
                    [primary_table] => 
                    [primary_id_column] => 
                    [table_aliases:protected] => Array
                        (
                        )

                    [clauses:protected] => Array
                        (
                        )

                    [has_or_relation:protected] => 
                )

            [date_query] => 
            [request] => SELECT  DISTINCT wpry_posts.*
					 FROM wpry_posts  INNER JOIN wpry_postmeta AS a ON ( a.post_id = wpry_posts.ID ) LEFT JOIN wpry_postmeta AS b ON ( (( b.post_id = a.post_id )) AND (( b.meta_key LIKE CONCAT( '\_', a.meta_key ) )) ) LEFT JOIN wpry_posts AS c ON ( ( c.post_name = b.meta_value ) AND ( c.post_type = 'acf-field' ) AND (( c.post_content LIKE '%:"text"%' ) OR ( c.post_content LIKE '%:"textarea"%' ) OR ( c.post_content LIKE '%:"wysiwyg"%' ) OR ( c.post_content LIKE '%:"checkbox"%' )) ) 
					 WHERE 1=1  AND ( ( ( b.meta_id IS NOT NULL ) AND ( c.ID IS NOT NULL ) AND ( a.meta_value LIKE '%CEPI%' ) ) OR ( ( wpry_posts.post_title LIKE '%CEPI%' ) OR ( wpry_posts.post_content LIKE '%CEPI%' ) OR ( wpry_posts.post_excerpt LIKE '%CEPI%' ) ) )  AND ((wpry_posts.post_type = 'provision_document' AND (wpry_posts.post_status = 'publish' OR wpry_posts.post_status = 'acf-disabled')))
					 
					 ORDER BY wpry_posts.post_title LIKE '{3a0ae59abce9aa28db367eecb9ab2ff20d90cd63276d2902cb2842f6aec6bca9}CEPI{3a0ae59abce9aa28db367eecb9ab2ff20d90cd63276d2902cb2842f6aec6bca9}' DESC, wpry_posts.post_date DESC
					 
            [posts] => Array
                (
                    [0] => WP_Post Object
                        (
                            [ID] => 12021
                            [post_author] => 5
                            [post_date] => 2024-09-04 10:40:57
                            [post_date_gmt] => 2024-09-04 10:40:57
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:40:57
                            [post_modified_gmt] => 2024-09-04 10:40:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12021
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [1] => WP_Post Object
                        (
                            [ID] => 12007
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:27
                            [post_date_gmt] => 2024-09-02 09:18:27
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:35:51
                            [post_modified_gmt] => 2024-09-02 14:35:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12007
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [2] => WP_Post Object
                        (
                            [ID] => 12006
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:21
                            [post_date_gmt] => 2024-09-02 09:18:21
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:18:21
                            [post_modified_gmt] => 2024-09-02 09:18:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12006
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [3] => WP_Post Object
                        (
                            [ID] => 12005
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:16
                            [post_date_gmt] => 2024-09-02 09:18:16
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:25:19
                            [post_modified_gmt] => 2024-09-02 14:25:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12005
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [4] => WP_Post Object
                        (
                            [ID] => 12004
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:10
                            [post_date_gmt] => 2024-09-02 09:18:10
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:23:39
                            [post_modified_gmt] => 2024-09-02 14:23:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12004
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [5] => WP_Post Object
                        (
                            [ID] => 11999
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:18:02
                            [post_date_gmt] => 2024-09-02 09:18:02
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 10:40:18
                            [post_modified_gmt] => 2024-09-02 10:40:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11999
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [6] => WP_Post Object
                        (
                            [ID] => 11998
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:54
                            [post_date_gmt] => 2024-09-02 09:17:54
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 10:48:33
                            [post_modified_gmt] => 2024-09-02 10:48:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11998
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [7] => WP_Post Object
                        (
                            [ID] => 11931
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:37
                            [post_date_gmt] => 2024-09-02 09:17:37
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:58:41
                            [post_modified_gmt] => 2024-09-03 08:58:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11931
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [8] => WP_Post Object
                        (
                            [ID] => 11930
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:27
                            [post_date_gmt] => 2024-09-02 09:17:27
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 10:33:23
                            [post_modified_gmt] => 2024-09-02 10:33:23
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11930
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [9] => WP_Post Object
                        (
                            [ID] => 11928
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:18
                            [post_date_gmt] => 2024-09-02 09:17:18
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:17:04
                            [post_modified_gmt] => 2024-09-03 08:17:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11928
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [10] => WP_Post Object
                        (
                            [ID] => 11927
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:09
                            [post_date_gmt] => 2024-09-02 09:17:09
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:44:21
                            [post_modified_gmt] => 2024-09-03 08:44:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11927
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [11] => WP_Post Object
                        (
                            [ID] => 11926
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:17:03
                            [post_date_gmt] => 2024-09-02 09:17:03
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:17:03
                            [post_modified_gmt] => 2024-09-02 09:17:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11926
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [12] => WP_Post Object
                        (
                            [ID] => 11925
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:39
                            [post_date_gmt] => 2024-09-02 09:16:39
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 11:06:24
                            [post_modified_gmt] => 2024-09-02 11:06:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11925
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [13] => WP_Post Object
                        (
                            [ID] => 11924
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:32
                            [post_date_gmt] => 2024-09-02 09:16:32
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:16:44
                            [post_modified_gmt] => 2024-09-03 08:16:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11924
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [14] => WP_Post Object
                        (
                            [ID] => 11920
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:23
                            [post_date_gmt] => 2024-09-02 09:16:23
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:39:42
                            [post_modified_gmt] => 2024-10-28 12:39:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11920
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [15] => WP_Post Object
                        (
                            [ID] => 11923
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:17
                            [post_date_gmt] => 2024-09-02 09:16:17
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-03 08:12:38
                            [post_modified_gmt] => 2024-09-03 08:12:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11923
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [16] => WP_Post Object
                        (
                            [ID] => 11922
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:10
                            [post_date_gmt] => 2024-09-02 09:16:10
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:16:10
                            [post_modified_gmt] => 2024-09-02 09:16:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11922
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [17] => WP_Post Object
                        (
                            [ID] => 11917
                            [post_author] => 5
                            [post_date] => 2024-09-02 09:16:04
                            [post_date_gmt] => 2024-09-02 09:16:04
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:21:48
                            [post_modified_gmt] => 2024-09-02 14:21:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11917
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [18] => WP_Post Object
                        (
                            [ID] => 12009
                            [post_author] => 5
                            [post_date] => 2024-09-02 08:24:39
                            [post_date_gmt] => 2024-09-02 08:24:39
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:30:38
                            [post_modified_gmt] => 2024-09-02 14:30:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12009
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [19] => WP_Post Object
                        (
                            [ID] => 11918
                            [post_author] => 5
                            [post_date] => 2024-08-26 15:05:16
                            [post_date_gmt] => 2024-08-26 15:05:16
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 09:43:25
                            [post_modified_gmt] => 2024-09-02 09:43:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=11918
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [20] => WP_Post Object
                        (
                            [ID] => 12008
                            [post_author] => 5
                            [post_date] => 2024-08-02 08:14:31
                            [post_date_gmt] => 2024-08-02 08:14:31
                            [post_content] => 
                            [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-02 14:38:35
                            [post_modified_gmt] => 2024-09-02 14:38:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12008
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [21] => WP_Post Object
                        (
                            [ID] => 8491
                            [post_author] => 5
                            [post_date] => 2023-01-19 11:34:54
                            [post_date_gmt] => 2023-01-19 11:34:54
                            [post_content] => 
                            [post_title] => CEPI CfP3i Vaccine Funding Agreement Template
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-vaccine-funding-agreement-template
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 15:32:38
                            [post_modified_gmt] => 2023-09-26 15:32:38
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8491
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [22] => WP_Post Object
                        (
                            [ID] => 8490
                            [post_author] => 5
                            [post_date] => 2023-01-19 11:11:46
                            [post_date_gmt] => 2023-01-19 11:11:46
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:44:48
                            [post_modified_gmt] => 2023-09-27 09:44:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8490
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [23] => WP_Post Object
                        (
                            [ID] => 8489
                            [post_author] => 5
                            [post_date] => 2023-01-19 10:44:52
                            [post_date_gmt] => 2023-01-19 10:44:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:46:11
                            [post_modified_gmt] => 2023-09-27 09:46:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8489
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [24] => WP_Post Object
                        (
                            [ID] => 8488
                            [post_author] => 5
                            [post_date] => 2023-01-19 10:15:15
                            [post_date_gmt] => 2023-01-19 10:15:15
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:40:32
                            [post_modified_gmt] => 2023-09-27 09:40:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8488
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [25] => WP_Post Object
                        (
                            [ID] => 8487
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:59:54
                            [post_date_gmt] => 2023-01-19 09:59:54
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:34:06
                            [post_modified_gmt] => 2023-09-27 09:34:06
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8487
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [26] => WP_Post Object
                        (
                            [ID] => 8486
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:46:36
                            [post_date_gmt] => 2023-01-19 09:46:36
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:41:21
                            [post_modified_gmt] => 2023-09-27 09:41:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8486
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [27] => WP_Post Object
                        (
                            [ID] => 8485
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:39:38
                            [post_date_gmt] => 2023-01-19 09:39:38
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-27 09:30:16
                            [post_modified_gmt] => 2023-09-27 09:30:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8485
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [28] => WP_Post Object
                        (
                            [ID] => 8484
                            [post_author] => 5
                            [post_date] => 2023-01-19 09:17:50
                            [post_date_gmt] => 2023-01-19 09:17:50
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:47:03
                            [post_modified_gmt] => 2024-09-04 10:47:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8484
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [29] => WP_Post Object
                        (
                            [ID] => 8482
                            [post_author] => 5
                            [post_date] => 2023-01-18 16:32:52
                            [post_date_gmt] => 2023-01-18 16:32:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:47:48
                            [post_modified_gmt] => 2024-09-04 10:47:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8482
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [30] => WP_Post Object
                        (
                            [ID] => 8481
                            [post_author] => 5
                            [post_date] => 2023-01-18 15:49:38
                            [post_date_gmt] => 2023-01-18 15:49:38
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-09-26 14:29:39
                            [post_modified_gmt] => 2023-09-26 14:29:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8481
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [31] => WP_Post Object
                        (
                            [ID] => 8480
                            [post_author] => 5
                            [post_date] => 2023-01-17 17:53:00
                            [post_date_gmt] => 2023-01-17 17:53:00
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:57:32
                            [post_modified_gmt] => 2023-11-10 13:57:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8480
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [32] => WP_Post Object
                        (
                            [ID] => 8479
                            [post_author] => 5
                            [post_date] => 2023-01-17 17:35:45
                            [post_date_gmt] => 2023-01-17 17:35:45
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 09:22:09
                            [post_modified_gmt] => 2023-07-11 09:22:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8479
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [33] => WP_Post Object
                        (
                            [ID] => 8469
                            [post_author] => 5
                            [post_date] => 2023-01-13 13:35:47
                            [post_date_gmt] => 2023-01-13 13:35:47
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 13:54:14
                            [post_modified_gmt] => 2023-06-26 13:54:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8469
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [34] => WP_Post Object
                        (
                            [ID] => 8468
                            [post_author] => 5
                            [post_date] => 2023-01-11 14:35:38
                            [post_date_gmt] => 2023-01-11 14:35:38
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:55:43
                            [post_modified_gmt] => 2023-06-22 14:55:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8468
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [35] => WP_Post Object
                        (
                            [ID] => 8467
                            [post_author] => 5
                            [post_date] => 2023-01-11 14:29:13
                            [post_date_gmt] => 2023-01-11 14:29:13
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:52:17
                            [post_modified_gmt] => 2023-06-22 14:52:17
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8467
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [36] => WP_Post Object
                        (
                            [ID] => 8462
                            [post_author] => 5
                            [post_date] => 2023-01-10 12:12:52
                            [post_date_gmt] => 2023-01-10 12:12:52
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:43:22
                            [post_modified_gmt] => 2023-11-10 14:43:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8462
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [37] => WP_Post Object
                        (
                            [ID] => 8461
                            [post_author] => 5
                            [post_date] => 2023-01-10 09:08:41
                            [post_date_gmt] => 2023-01-10 09:08:41
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:53:03
                            [post_modified_gmt] => 2023-06-21 09:53:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8461
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [38] => WP_Post Object
                        (
                            [ID] => 8314
                            [post_author] => 5
                            [post_date] => 2022-12-13 11:46:36
                            [post_date_gmt] => 2022-12-13 11:46:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:07:37
                            [post_modified_gmt] => 2024-11-18 15:07:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8314
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [39] => WP_Post Object
                        (
                            [ID] => 8313
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:48:56
                            [post_date_gmt] => 2022-12-13 10:48:56
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:08:00
                            [post_modified_gmt] => 2024-11-18 15:08:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8313
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [40] => WP_Post Object
                        (
                            [ID] => 8312
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:35:08
                            [post_date_gmt] => 2022-12-13 10:35:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:08:20
                            [post_modified_gmt] => 2024-11-18 15:08:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8312
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [41] => WP_Post Object
                        (
                            [ID] => 8311
                            [post_author] => 5
                            [post_date] => 2022-12-13 10:09:44
                            [post_date_gmt] => 2022-12-13 10:09:44
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:08:44
                            [post_modified_gmt] => 2024-11-18 15:08:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8311
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [42] => WP_Post Object
                        (
                            [ID] => 8192
                            [post_author] => 5
                            [post_date] => 2022-12-13 09:04:26
                            [post_date_gmt] => 2022-12-13 09:04:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:09:09
                            [post_modified_gmt] => 2024-11-18 15:09:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8192
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [43] => WP_Post Object
                        (
                            [ID] => 8191
                            [post_author] => 5
                            [post_date] => 2022-12-12 16:19:19
                            [post_date_gmt] => 2022-12-12 16:19:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:09:36
                            [post_modified_gmt] => 2024-11-18 15:09:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8191
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [44] => WP_Post Object
                        (
                            [ID] => 8190
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:29:46
                            [post_date_gmt] => 2022-12-12 15:29:46
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:10:02
                            [post_modified_gmt] => 2024-11-18 15:10:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8190
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [45] => WP_Post Object
                        (
                            [ID] => 8157
                            [post_author] => 5
                            [post_date] => 2022-12-12 15:23:50
                            [post_date_gmt] => 2022-12-12 15:23:50
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:10:21
                            [post_modified_gmt] => 2024-11-18 15:10:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [46] => WP_Post Object
                        (
                            [ID] => 8152
                            [post_author] => 5
                            [post_date] => 2022-12-12 12:04:21
                            [post_date_gmt] => 2022-12-12 12:04:21
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:10:51
                            [post_modified_gmt] => 2024-11-18 15:10:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [47] => WP_Post Object
                        (
                            [ID] => 8151
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:56:08
                            [post_date_gmt] => 2022-12-12 11:56:08
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:11:13
                            [post_modified_gmt] => 2024-11-18 15:11:13
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [48] => WP_Post Object
                        (
                            [ID] => 8150
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:21:26
                            [post_date_gmt] => 2022-12-12 11:21:26
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:11:37
                            [post_modified_gmt] => 2024-11-18 15:11:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [49] => WP_Post Object
                        (
                            [ID] => 8143
                            [post_author] => 5
                            [post_date] => 2022-12-12 11:10:19
                            [post_date_gmt] => 2022-12-12 11:10:19
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:12:03
                            [post_modified_gmt] => 2024-11-18 15:12:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [50] => WP_Post Object
                        (
                            [ID] => 8142
                            [post_author] => 5
                            [post_date] => 2022-12-12 10:40:31
                            [post_date_gmt] => 2022-12-12 10:40:31
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:12:47
                            [post_modified_gmt] => 2024-11-18 15:12:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8142
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [51] => WP_Post Object
                        (
                            [ID] => 8131
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:57:36
                            [post_date_gmt] => 2022-12-12 09:57:36
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:13:14
                            [post_modified_gmt] => 2024-11-18 15:13:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [52] => WP_Post Object
                        (
                            [ID] => 8130
                            [post_author] => 5
                            [post_date] => 2022-12-12 09:34:49
                            [post_date_gmt] => 2022-12-12 09:34:49
                            [post_content] => 
                            [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:13:39
                            [post_modified_gmt] => 2024-11-18 15:13:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [53] => WP_Post Object
                        (
                            [ID] => 8129
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:55:53
                            [post_date_gmt] => 2022-12-12 08:55:53
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 13:36:21
                            [post_modified_gmt] => 2024-11-18 13:36:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [54] => WP_Post Object
                        (
                            [ID] => 8051
                            [post_author] => 5
                            [post_date] => 2022-12-12 08:39:19
                            [post_date_gmt] => 2022-12-12 08:39:19
                            [post_content] => 
                            [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-11-18 15:14:21
                            [post_modified_gmt] => 2024-11-18 15:14:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=8051
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [55] => WP_Post Object
                        (
                            [ID] => 5782
                            [post_author] => 5
                            [post_date] => 2022-09-16 07:28:56
                            [post_date_gmt] => 2022-09-16 07:28:56
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:43:22
                            [post_modified_gmt] => 2023-06-22 13:43:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5782
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [56] => WP_Post Object
                        (
                            [ID] => 5653
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:56:30
                            [post_date_gmt] => 2022-08-25 12:56:30
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:00:47
                            [post_modified_gmt] => 2023-06-22 14:00:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5653
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [57] => WP_Post Object
                        (
                            [ID] => 5652
                            [post_author] => 5
                            [post_date] => 2022-08-25 12:26:53
                            [post_date_gmt] => 2022-08-25 12:26:53
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:48:11
                            [post_modified_gmt] => 2023-06-22 13:48:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5652
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [58] => WP_Post Object
                        (
                            [ID] => 5427
                            [post_author] => 5
                            [post_date] => 2022-07-22 15:20:29
                            [post_date_gmt] => 2022-07-22 15:20:29
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 09:57:36
                            [post_modified_gmt] => 2023-06-21 09:57:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5427
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [59] => WP_Post Object
                        (
                            [ID] => 4580
                            [post_author] => 5
                            [post_date] => 2022-03-31 14:34:38
                            [post_date_gmt] => 2022-03-31 14:34:38
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:58:04
                            [post_modified_gmt] => 2023-11-10 13:58:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4580
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [60] => WP_Post Object
                        (
                            [ID] => 4205
                            [post_author] => 5
                            [post_date] => 2022-02-28 15:24:19
                            [post_date_gmt] => 2022-02-28 15:24:19
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:01:27
                            [post_modified_gmt] => 2023-06-22 14:01:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [61] => WP_Post Object
                        (
                            [ID] => 4204
                            [post_author] => 5
                            [post_date] => 2022-02-28 14:53:11
                            [post_date_gmt] => 2022-02-28 14:53:11
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:52:02
                            [post_modified_gmt] => 2023-06-22 13:52:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [62] => WP_Post Object
                        (
                            [ID] => 4201
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:33:22
                            [post_date_gmt] => 2022-02-28 13:33:22
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:02:58
                            [post_modified_gmt] => 2023-06-22 14:02:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [63] => WP_Post Object
                        (
                            [ID] => 4200
                            [post_author] => 5
                            [post_date] => 2022-02-28 13:13:29
                            [post_date_gmt] => 2022-02-28 13:13:29
                            [post_content] => 
                            [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:54:49
                            [post_modified_gmt] => 2023-06-22 13:54:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [64] => WP_Post Object
                        (
                            [ID] => 4141
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:31:23
                            [post_date_gmt] => 2022-01-31 14:31:23
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-21 11:27:35
                            [post_modified_gmt] => 2024-10-21 11:27:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4141
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [65] => WP_Post Object
                        (
                            [ID] => 4140
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:22:03
                            [post_date_gmt] => 2022-01-31 14:22:03
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:00:51
                            [post_modified_gmt] => 2023-06-22 13:00:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4140
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [66] => WP_Post Object
                        (
                            [ID] => 4139
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:18:32
                            [post_date_gmt] => 2022-01-31 14:18:32
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:20:55
                            [post_modified_gmt] => 2023-06-22 13:20:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4139
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [67] => WP_Post Object
                        (
                            [ID] => 4138
                            [post_author] => 5
                            [post_date] => 2022-01-31 14:09:33
                            [post_date_gmt] => 2022-01-31 14:09:33
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:26:07
                            [post_modified_gmt] => 2023-06-22 13:26:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4138
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [68] => WP_Post Object
                        (
                            [ID] => 4137
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:53:37
                            [post_date_gmt] => 2022-01-31 13:53:37
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:30:50
                            [post_modified_gmt] => 2023-06-22 13:30:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4137
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [69] => WP_Post Object
                        (
                            [ID] => 4136
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:42:47
                            [post_date_gmt] => 2022-01-31 13:42:47
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:29:44
                            [post_modified_gmt] => 2023-06-22 13:29:44
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4136
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [70] => WP_Post Object
                        (
                            [ID] => 4135
                            [post_author] => 5
                            [post_date] => 2022-01-31 13:25:08
                            [post_date_gmt] => 2022-01-31 13:25:08
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:22:47
                            [post_modified_gmt] => 2023-06-22 13:22:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4135
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [71] => WP_Post Object
                        (
                            [ID] => 4134
                            [post_author] => 5
                            [post_date] => 2022-01-31 12:56:28
                            [post_date_gmt] => 2022-01-31 12:56:28
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:21:33
                            [post_modified_gmt] => 2023-06-22 13:21:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4134
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [72] => WP_Post Object
                        (
                            [ID] => 4133
                            [post_author] => 5
                            [post_date] => 2022-01-31 12:22:56
                            [post_date_gmt] => 2022-01-31 12:22:56
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:16:39
                            [post_modified_gmt] => 2023-06-22 13:16:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4133
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [73] => WP_Post Object
                        (
                            [ID] => 4131
                            [post_author] => 5
                            [post_date] => 2022-01-29 16:21:19
                            [post_date_gmt] => 2022-01-29 16:21:19
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:18:58
                            [post_modified_gmt] => 2023-06-22 13:18:58
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4131
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [74] => WP_Post Object
                        (
                            [ID] => 4130
                            [post_author] => 5
                            [post_date] => 2022-01-29 15:34:50
                            [post_date_gmt] => 2022-01-29 15:34:50
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:20:03
                            [post_modified_gmt] => 2023-06-22 13:20:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4130
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [75] => WP_Post Object
                        (
                            [ID] => 4129
                            [post_author] => 5
                            [post_date] => 2022-01-28 14:43:06
                            [post_date_gmt] => 2022-01-28 14:43:06
                            [post_content] => 
                            [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:58:31
                            [post_modified_gmt] => 2023-11-10 13:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4129
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [76] => WP_Post Object
                        (
                            [ID] => 4128
                            [post_author] => 5
                            [post_date] => 2022-01-28 13:38:44
                            [post_date_gmt] => 2022-01-28 13:38:44
                            [post_content] => 
                            [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:55:24
                            [post_modified_gmt] => 2023-06-21 12:55:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4128
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [77] => WP_Post Object
                        (
                            [ID] => 3757
                            [post_author] => 5
                            [post_date] => 2021-08-25 08:42:34
                            [post_date_gmt] => 2021-08-25 08:42:34
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 13:48:41
                            [post_modified_gmt] => 2023-06-26 13:48:41
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3757
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [78] => WP_Post Object
                        (
                            [ID] => 3756
                            [post_author] => 5
                            [post_date] => 2021-08-25 08:10:37
                            [post_date_gmt] => 2021-08-25 08:10:37
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 12:23:27
                            [post_modified_gmt] => 2023-06-26 12:23:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3756
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [79] => WP_Post Object
                        (
                            [ID] => 3755
                            [post_author] => 5
                            [post_date] => 2021-08-25 07:55:51
                            [post_date_gmt] => 2021-08-25 07:55:51
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:26:18
                            [post_modified_gmt] => 2024-01-10 16:26:18
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3755
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [80] => WP_Post Object
                        (
                            [ID] => 3754
                            [post_author] => 5
                            [post_date] => 2021-08-24 13:43:37
                            [post_date_gmt] => 2021-08-24 13:43:37
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:40:49
                            [post_modified_gmt] => 2023-06-27 11:40:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3754
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [81] => WP_Post Object
                        (
                            [ID] => 3753
                            [post_author] => 5
                            [post_date] => 2021-08-24 13:14:41
                            [post_date_gmt] => 2021-08-24 13:14:41
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 14:08:59
                            [post_modified_gmt] => 2023-06-26 14:08:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3753
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [82] => WP_Post Object
                        (
                            [ID] => 3751
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:54:56
                            [post_date_gmt] => 2021-08-24 12:54:56
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 14:08:20
                            [post_modified_gmt] => 2023-06-26 14:08:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3751
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [83] => WP_Post Object
                        (
                            [ID] => 3749
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:40:53
                            [post_date_gmt] => 2021-08-24 12:40:53
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-27 11:35:25
                            [post_modified_gmt] => 2023-06-27 11:35:25
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3749
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [84] => WP_Post Object
                        (
                            [ID] => 3748
                            [post_author] => 5
                            [post_date] => 2021-08-24 12:31:07
                            [post_date_gmt] => 2021-08-24 12:31:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:19:34
                            [post_modified_gmt] => 2023-10-16 14:19:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3748
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [85] => WP_Post Object
                        (
                            [ID] => 3747
                            [post_author] => 5
                            [post_date] => 2021-08-24 11:12:07
                            [post_date_gmt] => 2021-08-24 11:12:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 12:19:26
                            [post_modified_gmt] => 2023-06-26 12:19:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3747
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [86] => WP_Post Object
                        (
                            [ID] => 3746
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:45:05
                            [post_date_gmt] => 2021-08-24 10:45:05
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 13:56:28
                            [post_modified_gmt] => 2023-06-26 13:56:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3746
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [87] => WP_Post Object
                        (
                            [ID] => 3744
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:32:54
                            [post_date_gmt] => 2021-08-24 10:32:54
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:23:55
                            [post_modified_gmt] => 2024-01-10 16:23:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3744
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [88] => WP_Post Object
                        (
                            [ID] => 3743
                            [post_author] => 5
                            [post_date] => 2021-08-24 10:19:00
                            [post_date_gmt] => 2021-08-24 10:19:00
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:25:37
                            [post_modified_gmt] => 2024-01-10 16:25:37
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3743
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [89] => WP_Post Object
                        (
                            [ID] => 3736
                            [post_author] => 5
                            [post_date] => 2021-08-24 07:47:09
                            [post_date_gmt] => 2021-08-24 07:47:09
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:32:46
                            [post_modified_gmt] => 2024-01-10 16:32:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3736
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [90] => WP_Post Object
                        (
                            [ID] => 3726
                            [post_author] => 5
                            [post_date] => 2021-08-23 16:13:39
                            [post_date_gmt] => 2021-08-23 16:13:39
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 13:58:56
                            [post_modified_gmt] => 2023-11-10 13:58:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3726
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [91] => WP_Post Object
                        (
                            [ID] => 3725
                            [post_author] => 5
                            [post_date] => 2021-08-23 13:56:41
                            [post_date_gmt] => 2021-08-23 13:56:41
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 13:50:49
                            [post_modified_gmt] => 2023-06-26 13:50:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3725
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [92] => WP_Post Object
                        (
                            [ID] => 3724
                            [post_author] => 5
                            [post_date] => 2021-08-23 13:11:07
                            [post_date_gmt] => 2021-08-23 13:11:07
                            [post_content] => 
                            [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 15:11:11
                            [post_modified_gmt] => 2023-08-02 15:11:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3724
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [93] => WP_Post Object
                        (
                            [ID] => 3722
                            [post_author] => 5
                            [post_date] => 2021-08-23 12:12:50
                            [post_date_gmt] => 2021-08-23 12:12:50
                            [post_content] => 
                            [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-26 12:24:33
                            [post_modified_gmt] => 2023-06-26 12:24:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3722
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [94] => WP_Post Object
                        (
                            [ID] => 3493
                            [post_author] => 5
                            [post_date] => 2021-08-10 11:15:39
                            [post_date_gmt] => 2021-08-10 11:15:39
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 13:58:36
                            [post_modified_gmt] => 2023-06-22 13:58:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [95] => WP_Post Object
                        (
                            [ID] => 3344
                            [post_author] => 6
                            [post_date] => 2021-06-30 13:02:36
                            [post_date_gmt] => 2021-06-30 13:02:36
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-22
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:10:07
                            [post_modified_gmt] => 2023-06-21 12:10:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3344
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [96] => WP_Post Object
                        (
                            [ID] => 3343
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:57:07
                            [post_date_gmt] => 2021-06-30 12:57:07
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-21
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:11:24
                            [post_modified_gmt] => 2023-06-21 12:11:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3343
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [97] => WP_Post Object
                        (
                            [ID] => 3342
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:50:17
                            [post_date_gmt] => 2021-06-30 12:50:17
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-20
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:07:11
                            [post_modified_gmt] => 2023-06-21 12:07:11
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3342
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [98] => WP_Post Object
                        (
                            [ID] => 3341
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:44:43
                            [post_date_gmt] => 2021-06-30 12:44:43
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-19
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:06:00
                            [post_modified_gmt] => 2023-06-21 12:06:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3341
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [99] => WP_Post Object
                        (
                            [ID] => 3339
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:37:28
                            [post_date_gmt] => 2021-06-30 12:37:28
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:08:28
                            [post_modified_gmt] => 2023-06-21 12:08:28
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3339
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [100] => WP_Post Object
                        (
                            [ID] => 3338
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:27:08
                            [post_date_gmt] => 2021-06-30 12:27:08
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:08:16
                            [post_modified_gmt] => 2024-01-11 10:08:16
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3338
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [101] => WP_Post Object
                        (
                            [ID] => 3336
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:18:57
                            [post_date_gmt] => 2021-06-30 12:18:57
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:05:22
                            [post_modified_gmt] => 2023-06-21 12:05:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3336
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [102] => WP_Post Object
                        (
                            [ID] => 3331
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:09:31
                            [post_date_gmt] => 2021-06-30 12:09:31
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:04:36
                            [post_modified_gmt] => 2023-06-21 12:04:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3331
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [103] => WP_Post Object
                        (
                            [ID] => 3329
                            [post_author] => 6
                            [post_date] => 2021-06-30 12:04:02
                            [post_date_gmt] => 2021-06-30 12:04:02
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:10:20
                            [post_modified_gmt] => 2024-01-11 10:10:20
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3329
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [104] => WP_Post Object
                        (
                            [ID] => 3327
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:47:34
                            [post_date_gmt] => 2021-06-30 11:47:34
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:57:10
                            [post_modified_gmt] => 2023-08-02 14:57:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3327
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [105] => WP_Post Object
                        (
                            [ID] => 3326
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:35:26
                            [post_date_gmt] => 2021-06-30 11:35:26
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 12:00:27
                            [post_modified_gmt] => 2023-06-21 12:00:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3326
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [106] => WP_Post Object
                        (
                            [ID] => 3323
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:15:16
                            [post_date_gmt] => 2021-06-30 11:15:16
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:10:57
                            [post_modified_gmt] => 2024-01-11 10:10:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3323
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [107] => WP_Post Object
                        (
                            [ID] => 3321
                            [post_author] => 6
                            [post_date] => 2021-06-30 11:12:36
                            [post_date_gmt] => 2021-06-30 11:12:36
                            [post_content] => 
                            [post_title] => CEPI – CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-13-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 10:02:31
                            [post_modified_gmt] => 2023-06-21 10:02:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3321
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [108] => WP_Post Object
                        (
                            [ID] => 3318
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:46:25
                            [post_date_gmt] => 2021-06-30 10:46:25
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:45:02
                            [post_modified_gmt] => 2024-09-04 10:45:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3318
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [109] => WP_Post Object
                        (
                            [ID] => 3316
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:25:45
                            [post_date_gmt] => 2021-06-30 10:25:45
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 11:58:34
                            [post_modified_gmt] => 2023-06-21 11:58:34
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3316
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [110] => WP_Post Object
                        (
                            [ID] => 3315
                            [post_author] => 6
                            [post_date] => 2021-06-30 10:19:01
                            [post_date_gmt] => 2021-06-30 10:19:01
                            [post_content] => 
                            [post_title] => CEPI - CureVac, Framework Partnering Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-curevac-framework-partnering-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-21 11:52:22
                            [post_modified_gmt] => 2023-06-21 11:52:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3315
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [111] => WP_Post Object
                        (
                            [ID] => 2909
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:13:58
                            [post_date_gmt] => 2021-05-19 15:13:58
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:45:09
                            [post_modified_gmt] => 2023-06-22 14:45:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [112] => WP_Post Object
                        (
                            [ID] => 2908
                            [post_author] => 6
                            [post_date] => 2021-05-19 15:08:05
                            [post_date_gmt] => 2021-05-19 15:08:05
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:37:32
                            [post_modified_gmt] => 2023-06-22 14:37:32
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [113] => WP_Post Object
                        (
                            [ID] => 2907
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:46:20
                            [post_date_gmt] => 2021-05-19 14:46:20
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:40:14
                            [post_modified_gmt] => 2023-06-22 14:40:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [114] => WP_Post Object
                        (
                            [ID] => 2893
                            [post_author] => 6
                            [post_date] => 2021-05-19 14:40:45
                            [post_date_gmt] => 2021-05-19 14:40:45
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:34:03
                            [post_modified_gmt] => 2023-06-22 14:34:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [115] => WP_Post Object
                        (
                            [ID] => 2892
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:30:23
                            [post_date_gmt] => 2021-05-14 19:30:23
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-28 12:57:50
                            [post_modified_gmt] => 2024-10-28 12:57:50
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [116] => WP_Post Object
                        (
                            [ID] => 2890
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:14:07
                            [post_date_gmt] => 2021-05-14 19:14:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:34:52
                            [post_modified_gmt] => 2023-06-22 14:34:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [117] => WP_Post Object
                        (
                            [ID] => 2889
                            [post_author] => 6
                            [post_date] => 2021-05-14 19:09:07
                            [post_date_gmt] => 2021-05-14 19:09:07
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-10-21 11:28:56
                            [post_modified_gmt] => 2024-10-21 11:28:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [118] => WP_Post Object
                        (
                            [ID] => 2885
                            [post_author] => 5
                            [post_date] => 2021-05-14 18:17:37
                            [post_date_gmt] => 2021-05-14 18:17:37
                            [post_content] => 
                            [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-22 14:36:43
                            [post_modified_gmt] => 2023-06-22 14:36:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [119] => WP_Post Object
                        (
                            [ID] => 1221
                            [post_author] => 6
                            [post_date] => 2020-05-22 20:09:53
                            [post_date_gmt] => 2020-05-22 20:09:53
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfpi3-template-funding-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-29 12:09:52
                            [post_modified_gmt] => 2024-08-29 12:09:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [120] => WP_Post Object
                        (
                            [ID] => 1205
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:33:17
                            [post_date_gmt] => 2020-05-22 19:33:17
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-29 13:09:07
                            [post_modified_gmt] => 2023-06-29 13:09:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [121] => WP_Post Object
                        (
                            [ID] => 1204
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:31:46
                            [post_date_gmt] => 2020-05-22 19:31:46
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-08-02 14:56:09
                            [post_modified_gmt] => 2023-08-02 14:56:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [122] => WP_Post Object
                        (
                            [ID] => 1203
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:30:52
                            [post_date_gmt] => 2020-05-22 19:30:52
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-29 13:18:43
                            [post_modified_gmt] => 2023-06-29 13:18:43
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [123] => WP_Post Object
                        (
                            [ID] => 1202
                            [post_author] => 6
                            [post_date] => 2020-05-22 19:28:49
                            [post_date_gmt] => 2020-05-22 19:28:49
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-29 13:12:39
                            [post_modified_gmt] => 2023-06-29 13:12:39
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [124] => WP_Post Object
                        (
                            [ID] => 1159
                            [post_author] => 6
                            [post_date] => 2020-05-21 23:14:15
                            [post_date_gmt] => 2020-05-21 23:14:15
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 16:33:10
                            [post_modified_gmt] => 2024-01-10 16:33:10
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [125] => WP_Post Object
                        (
                            [ID] => 996
                            [post_author] => 7
                            [post_date] => 2020-05-18 19:58:18
                            [post_date_gmt] => 2020-05-18 19:58:18
                            [post_content] => 
                            [post_title] => CEPI CfP3i Template Funding Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => cepi-cfp3i-template-funding-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-10-16 14:20:47
                            [post_modified_gmt] => 2023-10-16 14:20:47
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [126] => WP_Post Object
                        (
                            [ID] => 12018
                            [post_author] => 5
                            [post_date] => 2024-09-04 10:23:55
                            [post_date_gmt] => 2024-09-04 10:23:55
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:23:55
                            [post_modified_gmt] => 2024-09-04 10:23:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=12018
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [127] => WP_Post Object
                        (
                            [ID] => 5808
                            [post_author] => 5
                            [post_date] => 2022-10-04 10:04:03
                            [post_date_gmt] => 2022-10-04 10:04:03
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:21:04
                            [post_modified_gmt] => 2023-07-10 17:21:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=5808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [128] => WP_Post Object
                        (
                            [ID] => 4661
                            [post_author] => 5
                            [post_date] => 2022-04-20 08:13:06
                            [post_date_gmt] => 2022-04-20 08:13:06
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:03:07
                            [post_modified_gmt] => 2023-07-10 15:03:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [129] => WP_Post Object
                        (
                            [ID] => 4147
                            [post_author] => 5
                            [post_date] => 2022-04-18 12:53:51
                            [post_date_gmt] => 2022-04-18 12:53:51
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:20:14
                            [post_modified_gmt] => 2023-07-10 17:20:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4147
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [130] => WP_Post Object
                        (
                            [ID] => 4148
                            [post_author] => 5
                            [post_date] => 2022-04-12 08:59:45
                            [post_date_gmt] => 2022-04-12 08:59:45
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-11-10 14:31:45
                            [post_modified_gmt] => 2023-11-10 14:31:45
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4148
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [131] => WP_Post Object
                        (
                            [ID] => 4223
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:43:58
                            [post_date_gmt] => 2022-03-04 09:43:58
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:24:30
                            [post_modified_gmt] => 2024-09-04 10:24:30
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4223
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [132] => WP_Post Object
                        (
                            [ID] => 4222
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:14:41
                            [post_date_gmt] => 2022-03-04 09:14:41
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:11:49
                            [post_modified_gmt] => 2023-06-20 12:11:49
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4222
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [133] => WP_Post Object
                        (
                            [ID] => 4221
                            [post_author] => 5
                            [post_date] => 2022-03-04 09:05:29
                            [post_date_gmt] => 2022-03-04 09:05:29
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:19:35
                            [post_modified_gmt] => 2023-06-20 12:19:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4221
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [134] => WP_Post Object
                        (
                            [ID] => 4220
                            [post_author] => 5
                            [post_date] => 2022-03-04 08:47:04
                            [post_date_gmt] => 2022-03-04 08:47:04
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:27:40
                            [post_modified_gmt] => 2023-06-20 12:27:40
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4220
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [135] => WP_Post Object
                        (
                            [ID] => 4219
                            [post_author] => 5
                            [post_date] => 2022-03-04 08:02:15
                            [post_date_gmt] => 2022-03-04 08:02:15
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:29:24
                            [post_modified_gmt] => 2023-06-20 12:29:24
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4219
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [136] => WP_Post Object
                        (
                            [ID] => 4218
                            [post_author] => 5
                            [post_date] => 2022-03-03 14:17:53
                            [post_date_gmt] => 2022-03-03 14:17:53
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:28:01
                            [post_modified_gmt] => 2023-06-20 12:28:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4218
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [137] => WP_Post Object
                        (
                            [ID] => 4217
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:59:58
                            [post_date_gmt] => 2022-03-03 13:59:58
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:26:19
                            [post_modified_gmt] => 2023-06-20 12:26:19
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4217
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [138] => WP_Post Object
                        (
                            [ID] => 4216
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:45:21
                            [post_date_gmt] => 2022-03-03 13:45:21
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:24:42
                            [post_modified_gmt] => 2023-06-20 12:24:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4216
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [139] => WP_Post Object
                        (
                            [ID] => 4215
                            [post_author] => 5
                            [post_date] => 2022-03-03 13:31:56
                            [post_date_gmt] => 2022-03-03 13:31:56
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:23:22
                            [post_modified_gmt] => 2023-06-20 12:23:22
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4215
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [140] => WP_Post Object
                        (
                            [ID] => 4214
                            [post_author] => 5
                            [post_date] => 2022-03-03 12:54:33
                            [post_date_gmt] => 2022-03-03 12:54:33
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:08:15
                            [post_modified_gmt] => 2023-06-20 12:08:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4214
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [141] => WP_Post Object
                        (
                            [ID] => 4213
                            [post_author] => 5
                            [post_date] => 2022-03-03 10:54:01
                            [post_date_gmt] => 2022-03-03 10:54:01
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:14:31
                            [post_modified_gmt] => 2023-06-20 12:14:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4213
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [142] => WP_Post Object
                        (
                            [ID] => 4212
                            [post_author] => 5
                            [post_date] => 2022-03-02 14:54:16
                            [post_date_gmt] => 2022-03-02 14:54:16
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:18:07
                            [post_modified_gmt] => 2023-06-20 12:18:07
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4212
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [143] => WP_Post Object
                        (
                            [ID] => 4210
                            [post_author] => 5
                            [post_date] => 2022-03-02 13:14:31
                            [post_date_gmt] => 2022-03-02 13:14:31
                            [post_content] => 
                            [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-06-20 12:21:57
                            [post_modified_gmt] => 2023-06-20 12:21:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4210
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [144] => WP_Post Object
                        (
                            [ID] => 4209
                            [post_author] => 5
                            [post_date] => 2022-03-02 12:07:13
                            [post_date_gmt] => 2022-03-02 12:07:13
                            [post_content] => 
                            [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 10:04:33
                            [post_modified_gmt] => 2024-01-11 10:04:33
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4209
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [145] => WP_Post Object
                        (
                            [ID] => 4161
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:48:58
                            [post_date_gmt] => 2022-02-02 13:48:58
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-08-20 13:31:52
                            [post_modified_gmt] => 2024-08-20 13:31:52
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4161
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [146] => WP_Post Object
                        (
                            [ID] => 4159
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:10:48
                            [post_date_gmt] => 2022-02-02 13:10:48
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:32:26
                            [post_modified_gmt] => 2023-07-10 17:32:26
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4159
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [147] => WP_Post Object
                        (
                            [ID] => 4158
                            [post_author] => 5
                            [post_date] => 2022-02-02 13:00:08
                            [post_date_gmt] => 2022-02-02 13:00:08
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 07:11:12
                            [post_modified_gmt] => 2023-07-11 07:11:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4158
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [148] => WP_Post Object
                        (
                            [ID] => 4157
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:54:56
                            [post_date_gmt] => 2022-02-02 12:54:56
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 07:01:00
                            [post_modified_gmt] => 2023-07-11 07:01:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4157
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [149] => WP_Post Object
                        (
                            [ID] => 4156
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:36:42
                            [post_date_gmt] => 2022-02-02 12:36:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 06:57:27
                            [post_modified_gmt] => 2023-07-11 06:57:27
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4156
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [150] => WP_Post Object
                        (
                            [ID] => 4155
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:19:16
                            [post_date_gmt] => 2022-02-02 12:19:16
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:39:59
                            [post_modified_gmt] => 2023-07-10 17:39:59
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4155
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [151] => WP_Post Object
                        (
                            [ID] => 4154
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:13:41
                            [post_date_gmt] => 2022-02-02 12:13:41
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:39:00
                            [post_modified_gmt] => 2023-07-10 17:39:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4154
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [152] => WP_Post Object
                        (
                            [ID] => 4153
                            [post_author] => 5
                            [post_date] => 2022-02-02 12:10:13
                            [post_date_gmt] => 2022-02-02 12:10:13
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:38:12
                            [post_modified_gmt] => 2023-07-10 17:38:12
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4153
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [153] => WP_Post Object
                        (
                            [ID] => 4152
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:51:54
                            [post_date_gmt] => 2022-02-02 11:51:54
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-11 07:10:01
                            [post_modified_gmt] => 2023-07-11 07:10:01
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4152
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [154] => WP_Post Object
                        (
                            [ID] => 4151
                            [post_author] => 5
                            [post_date] => 2022-02-02 11:39:24
                            [post_date_gmt] => 2022-02-02 11:39:24
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:33:46
                            [post_modified_gmt] => 2023-07-10 17:33:46
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4151
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [155] => WP_Post Object
                        (
                            [ID] => 4150
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:24:30
                            [post_date_gmt] => 2022-02-02 10:24:30
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:10:00
                            [post_modified_gmt] => 2023-07-10 17:10:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4150
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [156] => WP_Post Object
                        (
                            [ID] => 4149
                            [post_author] => 5
                            [post_date] => 2022-02-02 10:15:42
                            [post_date_gmt] => 2022-02-02 10:15:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:23:03
                            [post_modified_gmt] => 2023-07-10 17:23:03
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4149
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [157] => WP_Post Object
                        (
                            [ID] => 4146
                            [post_author] => 5
                            [post_date] => 2022-02-02 07:28:42
                            [post_date_gmt] => 2022-02-02 07:28:42
                            [post_content] => 
                            [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:36:14
                            [post_modified_gmt] => 2023-07-10 17:36:14
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=4146
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [158] => WP_Post Object
                        (
                            [ID] => 3812
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:44:57
                            [post_date_gmt] => 2021-09-10 12:44:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:01:51
                            [post_modified_gmt] => 2023-07-10 17:01:51
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3812
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [159] => WP_Post Object
                        (
                            [ID] => 3810
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:21:33
                            [post_date_gmt] => 2021-09-10 12:21:33
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:55:36
                            [post_modified_gmt] => 2023-07-10 14:55:36
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3810
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [160] => WP_Post Object
                        (
                            [ID] => 3809
                            [post_author] => 5
                            [post_date] => 2021-09-10 12:11:12
                            [post_date_gmt] => 2021-09-10 12:11:12
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:59:00
                            [post_modified_gmt] => 2023-07-10 14:59:00
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3809
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [161] => WP_Post Object
                        (
                            [ID] => 3808
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:59:11
                            [post_date_gmt] => 2021-09-10 11:59:11
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-11 11:35:57
                            [post_modified_gmt] => 2024-01-11 11:35:57
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3808
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [162] => WP_Post Object
                        (
                            [ID] => 3807
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:55:25
                            [post_date_gmt] => 2021-09-10 11:55:25
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-09-04 10:53:55
                            [post_modified_gmt] => 2024-09-04 10:53:55
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3807
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [163] => WP_Post Object
                        (
                            [ID] => 3806
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:47:18
                            [post_date_gmt] => 2021-09-10 11:47:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:20:35
                            [post_modified_gmt] => 2024-01-10 15:20:35
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3806
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [164] => WP_Post Object
                        (
                            [ID] => 3805
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:33:53
                            [post_date_gmt] => 2021-09-10 11:33:53
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:07:02
                            [post_modified_gmt] => 2023-07-10 17:07:02
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [165] => WP_Post Object
                        (
                            [ID] => 3804
                            [post_author] => 5
                            [post_date] => 2021-09-10 11:20:59
                            [post_date_gmt] => 2021-09-10 11:20:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 17:08:42
                            [post_modified_gmt] => 2023-07-10 17:08:42
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3804
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [166] => WP_Post Object
                        (
                            [ID] => 3803
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:54:42
                            [post_date_gmt] => 2021-09-10 10:54:42
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 16:58:31
                            [post_modified_gmt] => 2023-07-10 16:58:31
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3803
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [167] => WP_Post Object
                        (
                            [ID] => 3802
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:45:57
                            [post_date_gmt] => 2021-09-10 10:45:57
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:08:48
                            [post_modified_gmt] => 2023-07-10 15:08:48
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3802
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [168] => WP_Post Object
                        (
                            [ID] => 3801
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:36:30
                            [post_date_gmt] => 2021-09-10 10:36:30
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 14:57:56
                            [post_modified_gmt] => 2023-07-10 14:57:56
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3801
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [169] => WP_Post Object
                        (
                            [ID] => 3800
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:25:59
                            [post_date_gmt] => 2021-09-10 10:25:59
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:05:04
                            [post_modified_gmt] => 2023-07-10 15:05:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3800
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [170] => WP_Post Object
                        (
                            [ID] => 3799
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:07:18
                            [post_date_gmt] => 2021-09-10 10:07:18
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:01:09
                            [post_modified_gmt] => 2023-07-10 15:01:09
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3799
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [171] => WP_Post Object
                        (
                            [ID] => 3798
                            [post_author] => 5
                            [post_date] => 2021-09-10 10:02:07
                            [post_date_gmt] => 2021-09-10 10:02:07
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:08:15
                            [post_modified_gmt] => 2023-07-10 15:08:15
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3798
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [172] => WP_Post Object
                        (
                            [ID] => 3797
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:54:44
                            [post_date_gmt] => 2021-09-10 09:54:44
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2023-07-10 15:07:04
                            [post_modified_gmt] => 2023-07-10 15:07:04
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3797
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                    [173] => WP_Post Object
                        (
                            [ID] => 3796
                            [post_author] => 5
                            [post_date] => 2021-09-10 09:03:43
                            [post_date_gmt] => 2021-09-10 09:03:43
                            [post_content] => 
                            [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                            [post_excerpt] => 
                            [post_status] => publish
                            [comment_status] => closed
                            [ping_status] => closed
                            [post_password] => 
                            [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                            [to_ping] => 
                            [pinged] => 
                            [post_modified] => 2024-01-10 15:22:21
                            [post_modified_gmt] => 2024-01-10 15:22:21
                            [post_content_filtered] => 
                            [post_parent] => 0
                            [guid] => https://ghiaa.org/?post_type=provision_document&p=3796
                            [menu_order] => 0
                            [post_type] => provision_document
                            [post_mime_type] => 
                            [comment_count] => 0
                            [filter] => raw
                        )

                )

            [post_count] => 174
            [current_post] => -1
            [before_loop] => 1
            [in_the_loop] => 
            [post] => WP_Post Object
                (
                    [ID] => 12021
                    [post_author] => 5
                    [post_date] => 2024-09-04 10:40:57
                    [post_date_gmt] => 2024-09-04 10:40:57
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:40:57
                    [post_modified_gmt] => 2024-09-04 10:40:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12021
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [comment_count] => 0
            [current_comment] => -1
            [found_posts] => 174
            [max_num_pages] => 0
            [max_num_comment_pages] => 0
            [is_single] => 
            [is_preview] => 
            [is_page] => 
            [is_archive] => 1
            [is_date] => 
            [is_year] => 
            [is_month] => 
            [is_day] => 
            [is_time] => 
            [is_author] => 
            [is_category] => 
            [is_tag] => 
            [is_tax] => 
            [is_search] => 1
            [is_feed] => 
            [is_comment_feed] => 
            [is_trackback] => 
            [is_home] => 
            [is_privacy_policy] => 
            [is_404] => 
            [is_embed] => 
            [is_paged] => 
            [is_admin] => 
            [is_attachment] => 
            [is_singular] => 
            [is_robots] => 
            [is_favicon] => 
            [is_posts_page] => 
            [is_post_type_archive] => 1
            [query_vars_hash:WP_Query:private] => 897e696eab0e6479c3bed8e5729a7a8a
            [query_vars_changed:WP_Query:private] => 1
            [thumbnails_cached] => 
            [allow_query_attachment_by_filename:protected] => 
            [stopwords:WP_Query:private] => Array
                (
                    [0] => about
                    [1] => an
                    [2] => are
                    [3] => as
                    [4] => at
                    [5] => be
                    [6] => by
                    [7] => com
                    [8] => for
                    [9] => from
                    [10] => how
                    [11] => in
                    [12] => is
                    [13] => it
                    [14] => of
                    [15] => on
                    [16] => or
                    [17] => that
                    [18] => the
                    [19] => this
                    [20] => to
                    [21] => was
                    [22] => what
                    [23] => when
                    [24] => where
                    [25] => who
                    [26] => will
                    [27] => with
                    [28] => www
                )

            [compat_fields:WP_Query:private] => Array
                (
                    [0] => query_vars_hash
                    [1] => query_vars_changed
                )

            [compat_methods:WP_Query:private] => Array
                (
                    [0] => init_query_flags
                    [1] => parse_tax_query
                )

        )

    [provisions] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 12021
                    [post_author] => 5
                    [post_date] => 2024-09-04 10:40:57
                    [post_date_gmt] => 2024-09-04 10:40:57
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:40:57
                    [post_modified_gmt] => 2024-09-04 10:40:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12021
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [1] => WP_Post Object
                (
                    [ID] => 12018
                    [post_author] => 5
                    [post_date] => 2024-09-04 10:23:55
                    [post_date_gmt] => 2024-09-04 10:23:55
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:23:55
                    [post_modified_gmt] => 2024-09-04 10:23:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12018
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [2] => WP_Post Object
                (
                    [ID] => 12007
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:27
                    [post_date_gmt] => 2024-09-02 09:18:27
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:35:51
                    [post_modified_gmt] => 2024-09-02 14:35:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12007
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [3] => WP_Post Object
                (
                    [ID] => 12006
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:21
                    [post_date_gmt] => 2024-09-02 09:18:21
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 09:18:21
                    [post_modified_gmt] => 2024-09-02 09:18:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12006
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [4] => WP_Post Object
                (
                    [ID] => 12005
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:16
                    [post_date_gmt] => 2024-09-02 09:18:16
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:25:19
                    [post_modified_gmt] => 2024-09-02 14:25:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12005
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [5] => WP_Post Object
                (
                    [ID] => 12004
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:10
                    [post_date_gmt] => 2024-09-02 09:18:10
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:23:39
                    [post_modified_gmt] => 2024-09-02 14:23:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12004
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [6] => WP_Post Object
                (
                    [ID] => 11999
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:18:02
                    [post_date_gmt] => 2024-09-02 09:18:02
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 10:40:18
                    [post_modified_gmt] => 2024-09-02 10:40:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11999
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [7] => WP_Post Object
                (
                    [ID] => 11998
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:54
                    [post_date_gmt] => 2024-09-02 09:17:54
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 10:48:33
                    [post_modified_gmt] => 2024-09-02 10:48:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11998
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [8] => WP_Post Object
                (
                    [ID] => 11931
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:37
                    [post_date_gmt] => 2024-09-02 09:17:37
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:58:41
                    [post_modified_gmt] => 2024-09-03 08:58:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11931
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [9] => WP_Post Object
                (
                    [ID] => 11930
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:27
                    [post_date_gmt] => 2024-09-02 09:17:27
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 10:33:23
                    [post_modified_gmt] => 2024-09-02 10:33:23
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11930
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [10] => WP_Post Object
                (
                    [ID] => 11928
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:18
                    [post_date_gmt] => 2024-09-02 09:17:18
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:17:04
                    [post_modified_gmt] => 2024-09-03 08:17:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11928
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [11] => WP_Post Object
                (
                    [ID] => 11927
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:09
                    [post_date_gmt] => 2024-09-02 09:17:09
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:44:21
                    [post_modified_gmt] => 2024-09-03 08:44:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11927
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [12] => WP_Post Object
                (
                    [ID] => 11926
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:17:03
                    [post_date_gmt] => 2024-09-02 09:17:03
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 09:17:03
                    [post_modified_gmt] => 2024-09-02 09:17:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11926
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [13] => WP_Post Object
                (
                    [ID] => 11925
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:39
                    [post_date_gmt] => 2024-09-02 09:16:39
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 11:06:24
                    [post_modified_gmt] => 2024-09-02 11:06:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11925
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [14] => WP_Post Object
                (
                    [ID] => 11924
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:32
                    [post_date_gmt] => 2024-09-02 09:16:32
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:16:44
                    [post_modified_gmt] => 2024-09-03 08:16:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11924
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [15] => WP_Post Object
                (
                    [ID] => 11920
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:23
                    [post_date_gmt] => 2024-09-02 09:16:23
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:39:42
                    [post_modified_gmt] => 2024-10-28 12:39:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11920
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [16] => WP_Post Object
                (
                    [ID] => 11923
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:17
                    [post_date_gmt] => 2024-09-02 09:16:17
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-03 08:12:38
                    [post_modified_gmt] => 2024-09-03 08:12:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11923
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [17] => WP_Post Object
                (
                    [ID] => 11922
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:10
                    [post_date_gmt] => 2024-09-02 09:16:10
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 09:16:10
                    [post_modified_gmt] => 2024-09-02 09:16:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11922
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [18] => WP_Post Object
                (
                    [ID] => 11917
                    [post_author] => 5
                    [post_date] => 2024-09-02 09:16:04
                    [post_date_gmt] => 2024-09-02 09:16:04
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:21:48
                    [post_modified_gmt] => 2024-09-02 14:21:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11917
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [19] => WP_Post Object
                (
                    [ID] => 12009
                    [post_author] => 5
                    [post_date] => 2024-09-02 08:24:39
                    [post_date_gmt] => 2024-09-02 08:24:39
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:30:38
                    [post_modified_gmt] => 2024-09-02 14:30:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12009
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [20] => WP_Post Object
                (
                    [ID] => 11918
                    [post_author] => 5
                    [post_date] => 2024-08-26 15:05:16
                    [post_date_gmt] => 2024-08-26 15:05:16
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 09:43:25
                    [post_modified_gmt] => 2024-09-02 09:43:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=11918
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [21] => WP_Post Object
                (
                    [ID] => 12008
                    [post_author] => 5
                    [post_date] => 2024-08-02 08:14:31
                    [post_date_gmt] => 2024-08-02 08:14:31
                    [post_content] => 
                    [post_title] => CEPI - University of Oxford - Barinthus Biotherapeutics, ChAdOx1 MERS Vaccine R&D Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-university-of-oxford-barinthus-biotherapeutics-chadox1-mers-vaccine-rd-funding-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-02 14:38:35
                    [post_modified_gmt] => 2024-09-02 14:38:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=12008
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [22] => WP_Post Object
                (
                    [ID] => 8491
                    [post_author] => 5
                    [post_date] => 2023-01-19 11:34:54
                    [post_date_gmt] => 2023-01-19 11:34:54
                    [post_content] => 
                    [post_title] => CEPI CfP3i Vaccine Funding Agreement Template
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-vaccine-funding-agreement-template
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-26 15:32:38
                    [post_modified_gmt] => 2023-09-26 15:32:38
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8491
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [23] => WP_Post Object
                (
                    [ID] => 8490
                    [post_author] => 5
                    [post_date] => 2023-01-19 11:11:46
                    [post_date_gmt] => 2023-01-19 11:11:46
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:44:48
                    [post_modified_gmt] => 2023-09-27 09:44:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8490
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [24] => WP_Post Object
                (
                    [ID] => 8489
                    [post_author] => 5
                    [post_date] => 2023-01-19 10:44:52
                    [post_date_gmt] => 2023-01-19 10:44:52
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:46:11
                    [post_modified_gmt] => 2023-09-27 09:46:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8489
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [25] => WP_Post Object
                (
                    [ID] => 8488
                    [post_author] => 5
                    [post_date] => 2023-01-19 10:15:15
                    [post_date_gmt] => 2023-01-19 10:15:15
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:40:32
                    [post_modified_gmt] => 2023-09-27 09:40:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8488
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [26] => WP_Post Object
                (
                    [ID] => 8487
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:59:54
                    [post_date_gmt] => 2023-01-19 09:59:54
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:34:06
                    [post_modified_gmt] => 2023-09-27 09:34:06
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8487
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [27] => WP_Post Object
                (
                    [ID] => 8486
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:46:36
                    [post_date_gmt] => 2023-01-19 09:46:36
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:41:21
                    [post_modified_gmt] => 2023-09-27 09:41:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8486
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [28] => WP_Post Object
                (
                    [ID] => 8485
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:39:38
                    [post_date_gmt] => 2023-01-19 09:39:38
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-27 09:30:16
                    [post_modified_gmt] => 2023-09-27 09:30:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8485
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [29] => WP_Post Object
                (
                    [ID] => 8484
                    [post_author] => 5
                    [post_date] => 2023-01-19 09:17:50
                    [post_date_gmt] => 2023-01-19 09:17:50
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:47:03
                    [post_modified_gmt] => 2024-09-04 10:47:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8484
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [30] => WP_Post Object
                (
                    [ID] => 8482
                    [post_author] => 5
                    [post_date] => 2023-01-18 16:32:52
                    [post_date_gmt] => 2023-01-18 16:32:52
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:47:48
                    [post_modified_gmt] => 2024-09-04 10:47:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8482
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [31] => WP_Post Object
                (
                    [ID] => 8481
                    [post_author] => 5
                    [post_date] => 2023-01-18 15:49:38
                    [post_date_gmt] => 2023-01-18 15:49:38
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-09-26 14:29:39
                    [post_modified_gmt] => 2023-09-26 14:29:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8481
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [32] => WP_Post Object
                (
                    [ID] => 8480
                    [post_author] => 5
                    [post_date] => 2023-01-17 17:53:00
                    [post_date_gmt] => 2023-01-17 17:53:00
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:57:32
                    [post_modified_gmt] => 2023-11-10 13:57:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8480
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [33] => WP_Post Object
                (
                    [ID] => 8479
                    [post_author] => 5
                    [post_date] => 2023-01-17 17:35:45
                    [post_date_gmt] => 2023-01-17 17:35:45
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 09:22:09
                    [post_modified_gmt] => 2023-07-11 09:22:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8479
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [34] => WP_Post Object
                (
                    [ID] => 8469
                    [post_author] => 5
                    [post_date] => 2023-01-13 13:35:47
                    [post_date_gmt] => 2023-01-13 13:35:47
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:54:14
                    [post_modified_gmt] => 2023-06-26 13:54:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8469
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [35] => WP_Post Object
                (
                    [ID] => 8468
                    [post_author] => 5
                    [post_date] => 2023-01-11 14:35:38
                    [post_date_gmt] => 2023-01-11 14:35:38
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:55:43
                    [post_modified_gmt] => 2023-06-22 14:55:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8468
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [36] => WP_Post Object
                (
                    [ID] => 8467
                    [post_author] => 5
                    [post_date] => 2023-01-11 14:29:13
                    [post_date_gmt] => 2023-01-11 14:29:13
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:52:17
                    [post_modified_gmt] => 2023-06-22 14:52:17
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8467
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [37] => WP_Post Object
                (
                    [ID] => 8462
                    [post_author] => 5
                    [post_date] => 2023-01-10 12:12:52
                    [post_date_gmt] => 2023-01-10 12:12:52
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:43:22
                    [post_modified_gmt] => 2023-11-10 14:43:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8462
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [38] => WP_Post Object
                (
                    [ID] => 8461
                    [post_author] => 5
                    [post_date] => 2023-01-10 09:08:41
                    [post_date_gmt] => 2023-01-10 09:08:41
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 09:53:03
                    [post_modified_gmt] => 2023-06-21 09:53:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8461
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [39] => WP_Post Object
                (
                    [ID] => 8314
                    [post_author] => 5
                    [post_date] => 2022-12-13 11:46:36
                    [post_date_gmt] => 2022-12-13 11:46:36
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:07:37
                    [post_modified_gmt] => 2024-11-18 15:07:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8314
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [40] => WP_Post Object
                (
                    [ID] => 8313
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:48:56
                    [post_date_gmt] => 2022-12-13 10:48:56
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:08:00
                    [post_modified_gmt] => 2024-11-18 15:08:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8313
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [41] => WP_Post Object
                (
                    [ID] => 8312
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:35:08
                    [post_date_gmt] => 2022-12-13 10:35:08
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:08:20
                    [post_modified_gmt] => 2024-11-18 15:08:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8312
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [42] => WP_Post Object
                (
                    [ID] => 8311
                    [post_author] => 5
                    [post_date] => 2022-12-13 10:09:44
                    [post_date_gmt] => 2022-12-13 10:09:44
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:08:44
                    [post_modified_gmt] => 2024-11-18 15:08:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8311
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [43] => WP_Post Object
                (
                    [ID] => 8192
                    [post_author] => 5
                    [post_date] => 2022-12-13 09:04:26
                    [post_date_gmt] => 2022-12-13 09:04:26
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:09:09
                    [post_modified_gmt] => 2024-11-18 15:09:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8192
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [44] => WP_Post Object
                (
                    [ID] => 8191
                    [post_author] => 5
                    [post_date] => 2022-12-12 16:19:19
                    [post_date_gmt] => 2022-12-12 16:19:19
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:09:36
                    [post_modified_gmt] => 2024-11-18 15:09:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8191
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [45] => WP_Post Object
                (
                    [ID] => 8190
                    [post_author] => 5
                    [post_date] => 2022-12-12 15:29:46
                    [post_date_gmt] => 2022-12-12 15:29:46
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:10:02
                    [post_modified_gmt] => 2024-11-18 15:10:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8190
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [46] => WP_Post Object
                (
                    [ID] => 8157
                    [post_author] => 5
                    [post_date] => 2022-12-12 15:23:50
                    [post_date_gmt] => 2022-12-12 15:23:50
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:10:21
                    [post_modified_gmt] => 2024-11-18 15:10:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8157
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [47] => WP_Post Object
                (
                    [ID] => 8152
                    [post_author] => 5
                    [post_date] => 2022-12-12 12:04:21
                    [post_date_gmt] => 2022-12-12 12:04:21
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:10:51
                    [post_modified_gmt] => 2024-11-18 15:10:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8152
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [48] => WP_Post Object
                (
                    [ID] => 8151
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:56:08
                    [post_date_gmt] => 2022-12-12 11:56:08
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:11:13
                    [post_modified_gmt] => 2024-11-18 15:11:13
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8151
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [49] => WP_Post Object
                (
                    [ID] => 8150
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:21:26
                    [post_date_gmt] => 2022-12-12 11:21:26
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:11:37
                    [post_modified_gmt] => 2024-11-18 15:11:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8150
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [50] => WP_Post Object
                (
                    [ID] => 8143
                    [post_author] => 5
                    [post_date] => 2022-12-12 11:10:19
                    [post_date_gmt] => 2022-12-12 11:10:19
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:12:03
                    [post_modified_gmt] => 2024-11-18 15:12:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8143
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [51] => WP_Post Object
                (
                    [ID] => 8142
                    [post_author] => 5
                    [post_date] => 2022-12-12 10:40:31
                    [post_date_gmt] => 2022-12-12 10:40:31
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:12:47
                    [post_modified_gmt] => 2024-11-18 15:12:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8142
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [52] => WP_Post Object
                (
                    [ID] => 8131
                    [post_author] => 5
                    [post_date] => 2022-12-12 09:57:36
                    [post_date_gmt] => 2022-12-12 09:57:36
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:13:14
                    [post_modified_gmt] => 2024-11-18 15:13:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8131
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [53] => WP_Post Object
                (
                    [ID] => 8130
                    [post_author] => 5
                    [post_date] => 2022-12-12 09:34:49
                    [post_date_gmt] => 2022-12-12 09:34:49
                    [post_content] => 
                    [post_title] => CEPI – VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:13:39
                    [post_modified_gmt] => 2024-11-18 15:13:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8130
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [54] => WP_Post Object
                (
                    [ID] => 8129
                    [post_author] => 5
                    [post_date] => 2022-12-12 08:55:53
                    [post_date_gmt] => 2022-12-12 08:55:53
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 13:36:21
                    [post_modified_gmt] => 2024-11-18 13:36:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8129
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [55] => WP_Post Object
                (
                    [ID] => 8051
                    [post_author] => 5
                    [post_date] => 2022-12-12 08:39:19
                    [post_date_gmt] => 2022-12-12 08:39:19
                    [post_content] => 
                    [post_title] => CEPI - VBI, COVID-19 Vaccine Development Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-vbi-covid-19-vaccine-development-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-11-18 15:14:21
                    [post_modified_gmt] => 2024-11-18 15:14:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=8051
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [56] => WP_Post Object
                (
                    [ID] => 5808
                    [post_author] => 5
                    [post_date] => 2022-10-04 10:04:03
                    [post_date_gmt] => 2022-10-04 10:04:03
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:21:04
                    [post_modified_gmt] => 2023-07-10 17:21:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5808
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [57] => WP_Post Object
                (
                    [ID] => 5782
                    [post_author] => 5
                    [post_date] => 2022-09-16 07:28:56
                    [post_date_gmt] => 2022-09-16 07:28:56
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:43:22
                    [post_modified_gmt] => 2023-06-22 13:43:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5782
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [58] => WP_Post Object
                (
                    [ID] => 5653
                    [post_author] => 5
                    [post_date] => 2022-08-25 12:56:30
                    [post_date_gmt] => 2022-08-25 12:56:30
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:00:47
                    [post_modified_gmt] => 2023-06-22 14:00:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5653
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [59] => WP_Post Object
                (
                    [ID] => 5652
                    [post_author] => 5
                    [post_date] => 2022-08-25 12:26:53
                    [post_date_gmt] => 2022-08-25 12:26:53
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:48:11
                    [post_modified_gmt] => 2023-06-22 13:48:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5652
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [60] => WP_Post Object
                (
                    [ID] => 5427
                    [post_author] => 5
                    [post_date] => 2022-07-22 15:20:29
                    [post_date_gmt] => 2022-07-22 15:20:29
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 09:57:36
                    [post_modified_gmt] => 2023-06-21 09:57:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=5427
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [61] => WP_Post Object
                (
                    [ID] => 4661
                    [post_author] => 5
                    [post_date] => 2022-04-20 08:13:06
                    [post_date_gmt] => 2022-04-20 08:13:06
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 15:03:07
                    [post_modified_gmt] => 2023-07-10 15:03:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4661
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [62] => WP_Post Object
                (
                    [ID] => 4147
                    [post_author] => 5
                    [post_date] => 2022-04-18 12:53:51
                    [post_date_gmt] => 2022-04-18 12:53:51
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:20:14
                    [post_modified_gmt] => 2023-07-10 17:20:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4147
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [63] => WP_Post Object
                (
                    [ID] => 4148
                    [post_author] => 5
                    [post_date] => 2022-04-12 08:59:45
                    [post_date_gmt] => 2022-04-12 08:59:45
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 14:31:45
                    [post_modified_gmt] => 2023-11-10 14:31:45
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4148
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [64] => WP_Post Object
                (
                    [ID] => 4580
                    [post_author] => 5
                    [post_date] => 2022-03-31 14:34:38
                    [post_date_gmt] => 2022-03-31 14:34:38
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:58:04
                    [post_modified_gmt] => 2023-11-10 13:58:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4580
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [65] => WP_Post Object
                (
                    [ID] => 4223
                    [post_author] => 5
                    [post_date] => 2022-03-04 09:43:58
                    [post_date_gmt] => 2022-03-04 09:43:58
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:24:30
                    [post_modified_gmt] => 2024-09-04 10:24:30
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4223
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [66] => WP_Post Object
                (
                    [ID] => 4222
                    [post_author] => 5
                    [post_date] => 2022-03-04 09:14:41
                    [post_date_gmt] => 2022-03-04 09:14:41
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:11:49
                    [post_modified_gmt] => 2023-06-20 12:11:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4222
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [67] => WP_Post Object
                (
                    [ID] => 4221
                    [post_author] => 5
                    [post_date] => 2022-03-04 09:05:29
                    [post_date_gmt] => 2022-03-04 09:05:29
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:19:35
                    [post_modified_gmt] => 2023-06-20 12:19:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4221
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [68] => WP_Post Object
                (
                    [ID] => 4220
                    [post_author] => 5
                    [post_date] => 2022-03-04 08:47:04
                    [post_date_gmt] => 2022-03-04 08:47:04
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:27:40
                    [post_modified_gmt] => 2023-06-20 12:27:40
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4220
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [69] => WP_Post Object
                (
                    [ID] => 4219
                    [post_author] => 5
                    [post_date] => 2022-03-04 08:02:15
                    [post_date_gmt] => 2022-03-04 08:02:15
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:29:24
                    [post_modified_gmt] => 2023-06-20 12:29:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4219
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [70] => WP_Post Object
                (
                    [ID] => 4218
                    [post_author] => 5
                    [post_date] => 2022-03-03 14:17:53
                    [post_date_gmt] => 2022-03-03 14:17:53
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:28:01
                    [post_modified_gmt] => 2023-06-20 12:28:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4218
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [71] => WP_Post Object
                (
                    [ID] => 4217
                    [post_author] => 5
                    [post_date] => 2022-03-03 13:59:58
                    [post_date_gmt] => 2022-03-03 13:59:58
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:26:19
                    [post_modified_gmt] => 2023-06-20 12:26:19
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4217
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [72] => WP_Post Object
                (
                    [ID] => 4216
                    [post_author] => 5
                    [post_date] => 2022-03-03 13:45:21
                    [post_date_gmt] => 2022-03-03 13:45:21
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:24:42
                    [post_modified_gmt] => 2023-06-20 12:24:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4216
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [73] => WP_Post Object
                (
                    [ID] => 4215
                    [post_author] => 5
                    [post_date] => 2022-03-03 13:31:56
                    [post_date_gmt] => 2022-03-03 13:31:56
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:23:22
                    [post_modified_gmt] => 2023-06-20 12:23:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4215
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [74] => WP_Post Object
                (
                    [ID] => 4214
                    [post_author] => 5
                    [post_date] => 2022-03-03 12:54:33
                    [post_date_gmt] => 2022-03-03 12:54:33
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:08:15
                    [post_modified_gmt] => 2023-06-20 12:08:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4214
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [75] => WP_Post Object
                (
                    [ID] => 4213
                    [post_author] => 5
                    [post_date] => 2022-03-03 10:54:01
                    [post_date_gmt] => 2022-03-03 10:54:01
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:14:31
                    [post_modified_gmt] => 2023-06-20 12:14:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4213
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [76] => WP_Post Object
                (
                    [ID] => 4212
                    [post_author] => 5
                    [post_date] => 2022-03-02 14:54:16
                    [post_date_gmt] => 2022-03-02 14:54:16
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:18:07
                    [post_modified_gmt] => 2023-06-20 12:18:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4212
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [77] => WP_Post Object
                (
                    [ID] => 4210
                    [post_author] => 5
                    [post_date] => 2022-03-02 13:14:31
                    [post_date_gmt] => 2022-03-02 13:14:31
                    [post_content] => 
                    [post_title] => Biological E – Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-20 12:21:57
                    [post_modified_gmt] => 2023-06-20 12:21:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4210
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [78] => WP_Post Object
                (
                    [ID] => 4209
                    [post_author] => 5
                    [post_date] => 2022-03-02 12:07:13
                    [post_date_gmt] => 2022-03-02 12:07:13
                    [post_content] => 
                    [post_title] => Biological E - Dynavax Technologies, COVID-19 Vaccine Adjuvant Supply Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => biological-e-dynavax-technologies-covid-19-vaccine-adjuvant-supply-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 10:04:33
                    [post_modified_gmt] => 2024-01-11 10:04:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4209
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [79] => WP_Post Object
                (
                    [ID] => 4205
                    [post_author] => 5
                    [post_date] => 2022-02-28 15:24:19
                    [post_date_gmt] => 2022-02-28 15:24:19
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:01:27
                    [post_modified_gmt] => 2023-06-22 14:01:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [80] => WP_Post Object
                (
                    [ID] => 4204
                    [post_author] => 5
                    [post_date] => 2022-02-28 14:53:11
                    [post_date_gmt] => 2022-02-28 14:53:11
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:52:02
                    [post_modified_gmt] => 2023-06-22 13:52:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4204
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [81] => WP_Post Object
                (
                    [ID] => 4201
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:33:22
                    [post_date_gmt] => 2022-02-28 13:33:22
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:02:58
                    [post_modified_gmt] => 2023-06-22 14:02:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4201
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [82] => WP_Post Object
                (
                    [ID] => 4200
                    [post_author] => 5
                    [post_date] => 2022-02-28 13:13:29
                    [post_date_gmt] => 2022-02-28 13:13:29
                    [post_content] => 
                    [post_title] => CEPI – Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:54:49
                    [post_modified_gmt] => 2023-06-22 13:54:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4200
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [83] => WP_Post Object
                (
                    [ID] => 4161
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:48:58
                    [post_date_gmt] => 2022-02-02 13:48:58
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-20 13:31:52
                    [post_modified_gmt] => 2024-08-20 13:31:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4161
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [84] => WP_Post Object
                (
                    [ID] => 4159
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:10:48
                    [post_date_gmt] => 2022-02-02 13:10:48
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:32:26
                    [post_modified_gmt] => 2023-07-10 17:32:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4159
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [85] => WP_Post Object
                (
                    [ID] => 4158
                    [post_author] => 5
                    [post_date] => 2022-02-02 13:00:08
                    [post_date_gmt] => 2022-02-02 13:00:08
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 07:11:12
                    [post_modified_gmt] => 2023-07-11 07:11:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4158
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [86] => WP_Post Object
                (
                    [ID] => 4157
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:54:56
                    [post_date_gmt] => 2022-02-02 12:54:56
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 07:01:00
                    [post_modified_gmt] => 2023-07-11 07:01:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4157
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [87] => WP_Post Object
                (
                    [ID] => 4156
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:36:42
                    [post_date_gmt] => 2022-02-02 12:36:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 06:57:27
                    [post_modified_gmt] => 2023-07-11 06:57:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4156
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [88] => WP_Post Object
                (
                    [ID] => 4155
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:19:16
                    [post_date_gmt] => 2022-02-02 12:19:16
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:39:59
                    [post_modified_gmt] => 2023-07-10 17:39:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4155
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [89] => WP_Post Object
                (
                    [ID] => 4154
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:13:41
                    [post_date_gmt] => 2022-02-02 12:13:41
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:39:00
                    [post_modified_gmt] => 2023-07-10 17:39:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4154
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [90] => WP_Post Object
                (
                    [ID] => 4153
                    [post_author] => 5
                    [post_date] => 2022-02-02 12:10:13
                    [post_date_gmt] => 2022-02-02 12:10:13
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:38:12
                    [post_modified_gmt] => 2023-07-10 17:38:12
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4153
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [91] => WP_Post Object
                (
                    [ID] => 4152
                    [post_author] => 5
                    [post_date] => 2022-02-02 11:51:54
                    [post_date_gmt] => 2022-02-02 11:51:54
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-11 07:10:01
                    [post_modified_gmt] => 2023-07-11 07:10:01
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4152
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [92] => WP_Post Object
                (
                    [ID] => 4151
                    [post_author] => 5
                    [post_date] => 2022-02-02 11:39:24
                    [post_date_gmt] => 2022-02-02 11:39:24
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:33:46
                    [post_modified_gmt] => 2023-07-10 17:33:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4151
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [93] => WP_Post Object
                (
                    [ID] => 4150
                    [post_author] => 5
                    [post_date] => 2022-02-02 10:24:30
                    [post_date_gmt] => 2022-02-02 10:24:30
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:10:00
                    [post_modified_gmt] => 2023-07-10 17:10:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4150
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [94] => WP_Post Object
                (
                    [ID] => 4149
                    [post_author] => 5
                    [post_date] => 2022-02-02 10:15:42
                    [post_date_gmt] => 2022-02-02 10:15:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:23:03
                    [post_modified_gmt] => 2023-07-10 17:23:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4149
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [95] => WP_Post Object
                (
                    [ID] => 4146
                    [post_author] => 5
                    [post_date] => 2022-02-02 07:28:42
                    [post_date_gmt] => 2022-02-02 07:28:42
                    [post_content] => 
                    [post_title] => Gavi Alliance – Novavax, COVID-19 Vaccine Advance Purchase Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => gavi-alliance-novavax-covid-19-vaccine-advance-purchase-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:36:14
                    [post_modified_gmt] => 2023-07-10 17:36:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4146
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [96] => WP_Post Object
                (
                    [ID] => 4141
                    [post_author] => 5
                    [post_date] => 2022-01-31 14:31:23
                    [post_date_gmt] => 2022-01-31 14:31:23
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-21 11:27:35
                    [post_modified_gmt] => 2024-10-21 11:27:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4141
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [97] => WP_Post Object
                (
                    [ID] => 4140
                    [post_author] => 5
                    [post_date] => 2022-01-31 14:22:03
                    [post_date_gmt] => 2022-01-31 14:22:03
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:00:51
                    [post_modified_gmt] => 2023-06-22 13:00:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4140
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [98] => WP_Post Object
                (
                    [ID] => 4139
                    [post_author] => 5
                    [post_date] => 2022-01-31 14:18:32
                    [post_date_gmt] => 2022-01-31 14:18:32
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:20:55
                    [post_modified_gmt] => 2023-06-22 13:20:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4139
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [99] => WP_Post Object
                (
                    [ID] => 4138
                    [post_author] => 5
                    [post_date] => 2022-01-31 14:09:33
                    [post_date_gmt] => 2022-01-31 14:09:33
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:26:07
                    [post_modified_gmt] => 2023-06-22 13:26:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4138
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [100] => WP_Post Object
                (
                    [ID] => 4137
                    [post_author] => 5
                    [post_date] => 2022-01-31 13:53:37
                    [post_date_gmt] => 2022-01-31 13:53:37
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:30:50
                    [post_modified_gmt] => 2023-06-22 13:30:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4137
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [101] => WP_Post Object
                (
                    [ID] => 4136
                    [post_author] => 5
                    [post_date] => 2022-01-31 13:42:47
                    [post_date_gmt] => 2022-01-31 13:42:47
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:29:44
                    [post_modified_gmt] => 2023-06-22 13:29:44
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4136
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [102] => WP_Post Object
                (
                    [ID] => 4135
                    [post_author] => 5
                    [post_date] => 2022-01-31 13:25:08
                    [post_date_gmt] => 2022-01-31 13:25:08
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:22:47
                    [post_modified_gmt] => 2023-06-22 13:22:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4135
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [103] => WP_Post Object
                (
                    [ID] => 4134
                    [post_author] => 5
                    [post_date] => 2022-01-31 12:56:28
                    [post_date_gmt] => 2022-01-31 12:56:28
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:21:33
                    [post_modified_gmt] => 2023-06-22 13:21:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4134
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [104] => WP_Post Object
                (
                    [ID] => 4133
                    [post_author] => 5
                    [post_date] => 2022-01-31 12:22:56
                    [post_date_gmt] => 2022-01-31 12:22:56
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:16:39
                    [post_modified_gmt] => 2023-06-22 13:16:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4133
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [105] => WP_Post Object
                (
                    [ID] => 4131
                    [post_author] => 5
                    [post_date] => 2022-01-29 16:21:19
                    [post_date_gmt] => 2022-01-29 16:21:19
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:18:58
                    [post_modified_gmt] => 2023-06-22 13:18:58
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4131
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [106] => WP_Post Object
                (
                    [ID] => 4130
                    [post_author] => 5
                    [post_date] => 2022-01-29 15:34:50
                    [post_date_gmt] => 2022-01-29 15:34:50
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:20:03
                    [post_modified_gmt] => 2023-06-22 13:20:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4130
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [107] => WP_Post Object
                (
                    [ID] => 4129
                    [post_author] => 5
                    [post_date] => 2022-01-28 14:43:06
                    [post_date_gmt] => 2022-01-28 14:43:06
                    [post_content] => 
                    [post_title] => CEPI – Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:58:31
                    [post_modified_gmt] => 2023-11-10 13:58:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4129
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [108] => WP_Post Object
                (
                    [ID] => 4128
                    [post_author] => 5
                    [post_date] => 2022-01-28 13:38:44
                    [post_date_gmt] => 2022-01-28 13:38:44
                    [post_content] => 
                    [post_title] => CEPI - Dynavax, COVID-19 Material Reservation Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-dynavax-covid-19-material-reservation-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:55:24
                    [post_modified_gmt] => 2023-06-21 12:55:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=4128
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [109] => WP_Post Object
                (
                    [ID] => 3812
                    [post_author] => 5
                    [post_date] => 2021-09-10 12:44:57
                    [post_date_gmt] => 2021-09-10 12:44:57
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:01:51
                    [post_modified_gmt] => 2023-07-10 17:01:51
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3812
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [110] => WP_Post Object
                (
                    [ID] => 3810
                    [post_author] => 5
                    [post_date] => 2021-09-10 12:21:33
                    [post_date_gmt] => 2021-09-10 12:21:33
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 14:55:36
                    [post_modified_gmt] => 2023-07-10 14:55:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3810
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [111] => WP_Post Object
                (
                    [ID] => 3809
                    [post_author] => 5
                    [post_date] => 2021-09-10 12:11:12
                    [post_date_gmt] => 2021-09-10 12:11:12
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 14:59:00
                    [post_modified_gmt] => 2023-07-10 14:59:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3809
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [112] => WP_Post Object
                (
                    [ID] => 3808
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:59:11
                    [post_date_gmt] => 2021-09-10 11:59:11
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 11:35:57
                    [post_modified_gmt] => 2024-01-11 11:35:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3808
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [113] => WP_Post Object
                (
                    [ID] => 3807
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:55:25
                    [post_date_gmt] => 2021-09-10 11:55:25
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:53:55
                    [post_modified_gmt] => 2024-09-04 10:53:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3807
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [114] => WP_Post Object
                (
                    [ID] => 3806
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:47:18
                    [post_date_gmt] => 2021-09-10 11:47:18
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 15:20:35
                    [post_modified_gmt] => 2024-01-10 15:20:35
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3806
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [115] => WP_Post Object
                (
                    [ID] => 3805
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:33:53
                    [post_date_gmt] => 2021-09-10 11:33:53
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:07:02
                    [post_modified_gmt] => 2023-07-10 17:07:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3805
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [116] => WP_Post Object
                (
                    [ID] => 3804
                    [post_author] => 5
                    [post_date] => 2021-09-10 11:20:59
                    [post_date_gmt] => 2021-09-10 11:20:59
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 17:08:42
                    [post_modified_gmt] => 2023-07-10 17:08:42
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3804
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [117] => WP_Post Object
                (
                    [ID] => 3803
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:54:42
                    [post_date_gmt] => 2021-09-10 10:54:42
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 16:58:31
                    [post_modified_gmt] => 2023-07-10 16:58:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3803
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [118] => WP_Post Object
                (
                    [ID] => 3802
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:45:57
                    [post_date_gmt] => 2021-09-10 10:45:57
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 15:08:48
                    [post_modified_gmt] => 2023-07-10 15:08:48
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3802
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [119] => WP_Post Object
                (
                    [ID] => 3801
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:36:30
                    [post_date_gmt] => 2021-09-10 10:36:30
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 14:57:56
                    [post_modified_gmt] => 2023-07-10 14:57:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3801
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [120] => WP_Post Object
                (
                    [ID] => 3800
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:25:59
                    [post_date_gmt] => 2021-09-10 10:25:59
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 15:05:04
                    [post_modified_gmt] => 2023-07-10 15:05:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3800
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [121] => WP_Post Object
                (
                    [ID] => 3799
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:07:18
                    [post_date_gmt] => 2021-09-10 10:07:18
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 15:01:09
                    [post_modified_gmt] => 2023-07-10 15:01:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3799
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [122] => WP_Post Object
                (
                    [ID] => 3798
                    [post_author] => 5
                    [post_date] => 2021-09-10 10:02:07
                    [post_date_gmt] => 2021-09-10 10:02:07
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 15:08:15
                    [post_modified_gmt] => 2023-07-10 15:08:15
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3798
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [123] => WP_Post Object
                (
                    [ID] => 3797
                    [post_author] => 5
                    [post_date] => 2021-09-10 09:54:44
                    [post_date_gmt] => 2021-09-10 09:54:44
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-07-10 15:07:04
                    [post_modified_gmt] => 2023-07-10 15:07:04
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3797
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [124] => WP_Post Object
                (
                    [ID] => 3796
                    [post_author] => 5
                    [post_date] => 2021-09-10 09:03:43
                    [post_date_gmt] => 2021-09-10 09:03:43
                    [post_content] => 
                    [post_title] => Novavax - Serum Institute of India, COVID-19 Vaccine Supply and License Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-serum-institute-of-india-covid-19-vaccine-supply-and-license-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 15:22:21
                    [post_modified_gmt] => 2024-01-10 15:22:21
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3796
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [125] => WP_Post Object
                (
                    [ID] => 3757
                    [post_author] => 5
                    [post_date] => 2021-08-25 08:42:34
                    [post_date_gmt] => 2021-08-25 08:42:34
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-18
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:48:41
                    [post_modified_gmt] => 2023-06-26 13:48:41
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3757
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [126] => WP_Post Object
                (
                    [ID] => 3756
                    [post_author] => 5
                    [post_date] => 2021-08-25 08:10:37
                    [post_date_gmt] => 2021-08-25 08:10:37
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:23:27
                    [post_modified_gmt] => 2023-06-26 12:23:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3756
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [127] => WP_Post Object
                (
                    [ID] => 3755
                    [post_author] => 5
                    [post_date] => 2021-08-25 07:55:51
                    [post_date_gmt] => 2021-08-25 07:55:51
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:26:18
                    [post_modified_gmt] => 2024-01-10 16:26:18
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3755
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [128] => WP_Post Object
                (
                    [ID] => 3754
                    [post_author] => 5
                    [post_date] => 2021-08-24 13:43:37
                    [post_date_gmt] => 2021-08-24 13:43:37
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-15
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-27 11:40:49
                    [post_modified_gmt] => 2023-06-27 11:40:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3754
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [129] => WP_Post Object
                (
                    [ID] => 3753
                    [post_author] => 5
                    [post_date] => 2021-08-24 13:14:41
                    [post_date_gmt] => 2021-08-24 13:14:41
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 14:08:59
                    [post_modified_gmt] => 2023-06-26 14:08:59
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3753
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [130] => WP_Post Object
                (
                    [ID] => 3751
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:54:56
                    [post_date_gmt] => 2021-08-24 12:54:56
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-12
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 14:08:20
                    [post_modified_gmt] => 2023-06-26 14:08:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3751
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [131] => WP_Post Object
                (
                    [ID] => 3749
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:40:53
                    [post_date_gmt] => 2021-08-24 12:40:53
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-27 11:35:25
                    [post_modified_gmt] => 2023-06-27 11:35:25
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3749
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [132] => WP_Post Object
                (
                    [ID] => 3748
                    [post_author] => 5
                    [post_date] => 2021-08-24 12:31:07
                    [post_date_gmt] => 2021-08-24 12:31:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-16 14:19:34
                    [post_modified_gmt] => 2023-10-16 14:19:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3748
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [133] => WP_Post Object
                (
                    [ID] => 3747
                    [post_author] => 5
                    [post_date] => 2021-08-24 11:12:07
                    [post_date_gmt] => 2021-08-24 11:12:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:19:26
                    [post_modified_gmt] => 2023-06-26 12:19:26
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3747
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [134] => WP_Post Object
                (
                    [ID] => 3746
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:45:05
                    [post_date_gmt] => 2021-08-24 10:45:05
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:56:28
                    [post_modified_gmt] => 2023-06-26 13:56:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3746
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [135] => WP_Post Object
                (
                    [ID] => 3744
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:32:54
                    [post_date_gmt] => 2021-08-24 10:32:54
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:23:55
                    [post_modified_gmt] => 2024-01-10 16:23:55
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3744
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [136] => WP_Post Object
                (
                    [ID] => 3743
                    [post_author] => 5
                    [post_date] => 2021-08-24 10:19:00
                    [post_date_gmt] => 2021-08-24 10:19:00
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:25:37
                    [post_modified_gmt] => 2024-01-10 16:25:37
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3743
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [137] => WP_Post Object
                (
                    [ID] => 3736
                    [post_author] => 5
                    [post_date] => 2021-08-24 07:47:09
                    [post_date_gmt] => 2021-08-24 07:47:09
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:32:46
                    [post_modified_gmt] => 2024-01-10 16:32:46
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3736
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [138] => WP_Post Object
                (
                    [ID] => 3726
                    [post_author] => 5
                    [post_date] => 2021-08-23 16:13:39
                    [post_date_gmt] => 2021-08-23 16:13:39
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-11-10 13:58:56
                    [post_modified_gmt] => 2023-11-10 13:58:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3726
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [139] => WP_Post Object
                (
                    [ID] => 3725
                    [post_author] => 5
                    [post_date] => 2021-08-23 13:56:41
                    [post_date_gmt] => 2021-08-23 13:56:41
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 13:50:49
                    [post_modified_gmt] => 2023-06-26 13:50:49
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3725
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [140] => WP_Post Object
                (
                    [ID] => 3724
                    [post_author] => 5
                    [post_date] => 2021-08-23 13:11:07
                    [post_date_gmt] => 2021-08-23 13:11:07
                    [post_content] => 
                    [post_title] => CEPI – Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 15:11:11
                    [post_modified_gmt] => 2023-08-02 15:11:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3724
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [141] => WP_Post Object
                (
                    [ID] => 3722
                    [post_author] => 5
                    [post_date] => 2021-08-23 12:12:50
                    [post_date_gmt] => 2021-08-23 12:12:50
                    [post_content] => 
                    [post_title] => CEPI - Valneva, Chikungunya Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-valneva-chikungunya-vaccine-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-26 12:24:33
                    [post_modified_gmt] => 2023-06-26 12:24:33
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3722
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [142] => WP_Post Object
                (
                    [ID] => 3493
                    [post_author] => 5
                    [post_date] => 2021-08-10 11:15:39
                    [post_date_gmt] => 2021-08-10 11:15:39
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-novavax-covid-19-vaccine-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 13:58:36
                    [post_modified_gmt] => 2023-06-22 13:58:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3493
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [143] => WP_Post Object
                (
                    [ID] => 3344
                    [post_author] => 6
                    [post_date] => 2021-06-30 13:02:36
                    [post_date_gmt] => 2021-06-30 13:02:36
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-22
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:10:07
                    [post_modified_gmt] => 2023-06-21 12:10:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3344
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [144] => WP_Post Object
                (
                    [ID] => 3343
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:57:07
                    [post_date_gmt] => 2021-06-30 12:57:07
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-21
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:11:24
                    [post_modified_gmt] => 2023-06-21 12:11:24
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3343
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [145] => WP_Post Object
                (
                    [ID] => 3342
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:50:17
                    [post_date_gmt] => 2021-06-30 12:50:17
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-20
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:07:11
                    [post_modified_gmt] => 2023-06-21 12:07:11
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3342
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [146] => WP_Post Object
                (
                    [ID] => 3341
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:44:43
                    [post_date_gmt] => 2021-06-30 12:44:43
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-19
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:06:00
                    [post_modified_gmt] => 2023-06-21 12:06:00
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3341
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [147] => WP_Post Object
                (
                    [ID] => 3339
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:37:28
                    [post_date_gmt] => 2021-06-30 12:37:28
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-17
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:08:28
                    [post_modified_gmt] => 2023-06-21 12:08:28
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3339
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [148] => WP_Post Object
                (
                    [ID] => 3338
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:27:08
                    [post_date_gmt] => 2021-06-30 12:27:08
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-16
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 10:08:16
                    [post_modified_gmt] => 2024-01-11 10:08:16
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3338
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [149] => WP_Post Object
                (
                    [ID] => 3336
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:18:57
                    [post_date_gmt] => 2021-06-30 12:18:57
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-14
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:05:22
                    [post_modified_gmt] => 2023-06-21 12:05:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3336
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [150] => WP_Post Object
                (
                    [ID] => 3331
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:09:31
                    [post_date_gmt] => 2021-06-30 12:09:31
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-13
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:04:36
                    [post_modified_gmt] => 2023-06-21 12:04:36
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3331
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [151] => WP_Post Object
                (
                    [ID] => 3329
                    [post_author] => 6
                    [post_date] => 2021-06-30 12:04:02
                    [post_date_gmt] => 2021-06-30 12:04:02
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-11
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 10:10:20
                    [post_modified_gmt] => 2024-01-11 10:10:20
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3329
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [152] => WP_Post Object
                (
                    [ID] => 3327
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:47:34
                    [post_date_gmt] => 2021-06-30 11:47:34
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 14:57:10
                    [post_modified_gmt] => 2023-08-02 14:57:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3327
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [153] => WP_Post Object
                (
                    [ID] => 3326
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:35:26
                    [post_date_gmt] => 2021-06-30 11:35:26
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 12:00:27
                    [post_modified_gmt] => 2023-06-21 12:00:27
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3326
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [154] => WP_Post Object
                (
                    [ID] => 3323
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:15:16
                    [post_date_gmt] => 2021-06-30 11:15:16
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-11 10:10:57
                    [post_modified_gmt] => 2024-01-11 10:10:57
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3323
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [155] => WP_Post Object
                (
                    [ID] => 3321
                    [post_author] => 6
                    [post_date] => 2021-06-30 11:12:36
                    [post_date_gmt] => 2021-06-30 11:12:36
                    [post_content] => 
                    [post_title] => CEPI – CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-13-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 10:02:31
                    [post_modified_gmt] => 2023-06-21 10:02:31
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3321
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [156] => WP_Post Object
                (
                    [ID] => 3318
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:46:25
                    [post_date_gmt] => 2021-06-30 10:46:25
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-09-04 10:45:02
                    [post_modified_gmt] => 2024-09-04 10:45:02
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3318
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [157] => WP_Post Object
                (
                    [ID] => 3316
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:25:45
                    [post_date_gmt] => 2021-06-30 10:25:45
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement-2
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 11:58:34
                    [post_modified_gmt] => 2023-06-21 11:58:34
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3316
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [158] => WP_Post Object
                (
                    [ID] => 3315
                    [post_author] => 6
                    [post_date] => 2021-06-30 10:19:01
                    [post_date_gmt] => 2021-06-30 10:19:01
                    [post_content] => 
                    [post_title] => CEPI - CureVac, Framework Partnering Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-curevac-framework-partnering-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-21 11:52:22
                    [post_modified_gmt] => 2023-06-21 11:52:22
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=3315
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [159] => WP_Post Object
                (
                    [ID] => 2909
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:13:58
                    [post_date_gmt] => 2021-05-19 15:13:58
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-10
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:45:09
                    [post_modified_gmt] => 2023-06-22 14:45:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2909
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [160] => WP_Post Object
                (
                    [ID] => 2908
                    [post_author] => 6
                    [post_date] => 2021-05-19 15:08:05
                    [post_date_gmt] => 2021-05-19 15:08:05
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-9
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:37:32
                    [post_modified_gmt] => 2023-06-22 14:37:32
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2908
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [161] => WP_Post Object
                (
                    [ID] => 2907
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:46:20
                    [post_date_gmt] => 2021-05-19 14:46:20
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:40:14
                    [post_modified_gmt] => 2023-06-22 14:40:14
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2907
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [162] => WP_Post Object
                (
                    [ID] => 2893
                    [post_author] => 6
                    [post_date] => 2021-05-19 14:40:45
                    [post_date_gmt] => 2021-05-19 14:40:45
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:34:03
                    [post_modified_gmt] => 2023-06-22 14:34:03
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2893
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [163] => WP_Post Object
                (
                    [ID] => 2892
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:30:23
                    [post_date_gmt] => 2021-05-14 19:30:23
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-28 12:57:50
                    [post_modified_gmt] => 2024-10-28 12:57:50
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2892
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [164] => WP_Post Object
                (
                    [ID] => 2890
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:14:07
                    [post_date_gmt] => 2021-05-14 19:14:07
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:34:52
                    [post_modified_gmt] => 2023-06-22 14:34:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2890
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [165] => WP_Post Object
                (
                    [ID] => 2889
                    [post_author] => 6
                    [post_date] => 2021-05-14 19:09:07
                    [post_date_gmt] => 2021-05-14 19:09:07
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-10-21 11:28:56
                    [post_modified_gmt] => 2024-10-21 11:28:56
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2889
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [166] => WP_Post Object
                (
                    [ID] => 2885
                    [post_author] => 5
                    [post_date] => 2021-05-14 18:17:37
                    [post_date_gmt] => 2021-05-14 18:17:37
                    [post_content] => 
                    [post_title] => CEPI - Novavax, COVID-19 Vaccine Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => novavax-cepi-outbreak-response-to-novel-coronavirus-covid-19-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-22 14:36:43
                    [post_modified_gmt] => 2023-06-22 14:36:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.org/?post_type=provision_document&p=2885
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [167] => WP_Post Object
                (
                    [ID] => 1221
                    [post_author] => 6
                    [post_date] => 2020-05-22 20:09:53
                    [post_date_gmt] => 2020-05-22 20:09:53
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfpi3-template-funding-agreement
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-08-29 12:09:52
                    [post_modified_gmt] => 2024-08-29 12:09:52
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1221
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [168] => WP_Post Object
                (
                    [ID] => 1205
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:33:17
                    [post_date_gmt] => 2020-05-22 19:33:17
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-4
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-29 13:09:07
                    [post_modified_gmt] => 2023-06-29 13:09:07
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1205
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [169] => WP_Post Object
                (
                    [ID] => 1204
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:31:46
                    [post_date_gmt] => 2020-05-22 19:31:46
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-5
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-08-02 14:56:09
                    [post_modified_gmt] => 2023-08-02 14:56:09
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1204
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [170] => WP_Post Object
                (
                    [ID] => 1203
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:30:52
                    [post_date_gmt] => 2020-05-22 19:30:52
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-3
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-29 13:18:43
                    [post_modified_gmt] => 2023-06-29 13:18:43
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1203
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [171] => WP_Post Object
                (
                    [ID] => 1202
                    [post_author] => 6
                    [post_date] => 2020-05-22 19:28:49
                    [post_date_gmt] => 2020-05-22 19:28:49
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-6
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-06-29 13:12:39
                    [post_modified_gmt] => 2023-06-29 13:12:39
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1202
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [172] => WP_Post Object
                (
                    [ID] => 1159
                    [post_author] => 6
                    [post_date] => 2020-05-21 23:14:15
                    [post_date_gmt] => 2020-05-21 23:14:15
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-7
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2024-01-10 16:33:10
                    [post_modified_gmt] => 2024-01-10 16:33:10
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=1159
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

            [173] => WP_Post Object
                (
                    [ID] => 996
                    [post_author] => 7
                    [post_date] => 2020-05-18 19:58:18
                    [post_date_gmt] => 2020-05-18 19:58:18
                    [post_content] => 
                    [post_title] => CEPI CfP3i Template Funding Agreement
                    [post_excerpt] => 
                    [post_status] => publish
                    [comment_status] => closed
                    [ping_status] => closed
                    [post_password] => 
                    [post_name] => cepi-cfp3i-template-funding-agreement-8
                    [to_ping] => 
                    [pinged] => 
                    [post_modified] => 2023-10-16 14:20:47
                    [post_modified_gmt] => 2023-10-16 14:20:47
                    [post_content_filtered] => 
                    [post_parent] => 0
                    [guid] => https://ghiaa.swantondevelopment.ca/?post_type=provision_document&p=996
                    [menu_order] => 0
                    [post_type] => provision_document
                    [post_mime_type] => 
                    [comment_count] => 0
                    [filter] => raw
                )

        )

    [invalid_get] => 
    [is_text_search] => 1
    [has_agreement_filters] => 
    [has_any_agreement_filter] => Array
        (
        )

    [found_agreements] => 
    [has_provision_filters] => 
    [found_provisions] => 1
    [lbl_quick_search:GHIAA2019\MapguideSearch:private] => Search results for:
    [lbl_issue:GHIAA2019\MapguideSearch:private] => Issue:
    [lbl_key_term:GHIAA2019\MapguideSearch:private] => Key Term:
    [lbl_agreement_type:GHIAA2019\MapguideSearch:private] => Agreement Type:
    [lbl_partner_type:GHIAA2019\MapguideSearch:private] => Partner Type:
    [lbl_technology:GHIAA2019\MapguideSearch:private] => Technology:
    [lbl_development_stage:GHIAA2019\MapguideSearch:private] => Development Stage:
    [issues_by_id:GHIAA2019\MapguideSearch:private] => Array
        (
            [101] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
 	How should equitable or global access be defined?
 	Should the developer be required to comply with an equitable access policy?
 	Should the developer be required to establish an access plan?

                    [parent] => 46
                    [count] => 49
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [100] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [66] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [53] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [371] => WP_Term Object
                (
                    [term_id] => 371
                    [name] => Clinical trial conduct
                    [slug] => clinical-trial-conduct
                    [term_group] => 0
                    [term_taxonomy_id] => 371
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 12
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [84] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
 	What is the scope of confidential information?
 	What are the obligations of the parties to protect confidential information?
 	Are there any exceptions to the confidentiality obligations?
 	Are the parties permitted to make public announcements related to the project?
 	Can the parties use each other’s name and logo for general marketing materials?

                    [parent] => 49
                    [count] => 99
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [271] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [72] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 81
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [281] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
 	Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
 	What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
 	Should related license grants vest upon execution of the agreement, or at a later stage in development?
 	Should there be an escrow requirement?
 	Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?

                    [parent] => 46
                    [count] => 55
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [46] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [278] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
 	Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
 	Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
 	Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
 	What are the resolution mechanisms for disputes related to the agreement?
 	Are there any requirements for policies or procedures to manage potential conflicts of interest?

                    [parent] => 53
                    [count] => 84
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [80] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
 	What occurrences could result in a liability claim against which one party will indemnify the other?
 	Are there any circumstances under which one party will not indemnify the other?
 	What is the process for managing liability claims?
 	Are there government or other types of indemnification schemes?
 	Is there any limitation or monetary cap on each party’s liabilities under the agreement?

                    [parent] => 50
                    [count] => 96
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [257] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
 	What financial and project progress information must be shared between the parties?
 	What is the required timeline for sharing information?
 	How is the receiving party permitted to use the information received?
 	Do the parties have the right to verify the information reported?

                    [parent] => 49
                    [count] => 89
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [109] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 59
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [48] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [50] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [88] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
 	Are any licenses granted for the use of background or foreground intellectual property?
 	What is the scope of the licensed intellectual property?
 	What is the territory of the license?
 	Is the license exclusive or non-exclusive?
 	Are there any restrictions on the use of the licensed intellectual property?
 	Are there any specific obligations to exploit the licensed intellectual property?
 	Can the licensee grant sublicenses to third parties?
 	Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)

                    [parent] => 48
                    [count] => 93
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [87] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 69
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [70] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => What is the payment structure under this agreement? 
What are the mechanisms to limit exposure to additional payments or expenses?
                    [parent] => 53
                    [count] => 78
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [102] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 12
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [268] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 42
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [49] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [90] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 68
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [290] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
                    [parent] => 49
                    [count] => 59
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [372] => WP_Term Object
                (
                    [term_id] => 372
                    [name] => Quality management
                    [slug] => quality-management
                    [term_group] => 0
                    [term_taxonomy_id] => 372
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 35
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [56] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 52
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [81] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => Should the parties make any warranties, and if so, what is the scope?
                    [parent] => 50
                    [count] => 84
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [86] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
                    [parent] => 49
                    [count] => 38
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [52] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => Term

 	What is the term of the agreement? Is it tied to the timeline of the project or license grants?

Termination

 	Under what circumstances may a party terminate or withdraw from the agreement?

Effects of Termination

 	What are the effects of termination or withdrawal by a party?

                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [76] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 83
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [74] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 86
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [282] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
 	How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
 	Should the developer be required to apply for regulatory approval in priority access markets?
 	Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
 	Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
 	Should the agreement include any anti-diversion provisions?

                    [parent] => 46
                    [count] => 55
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

        )

    [issues_by_slug:GHIAA2019\MapguideSearch:private] => Array
        (
            [equitable-access] => WP_Term Object
                (
                    [term_id] => 101
                    [name] => Access plans & principles
                    [slug] => equitable-access
                    [term_group] => 0
                    [term_taxonomy_id] => 101
                    [taxonomy] => issue
                    [description] => 
 	How should equitable or global access be defined?
 	Should the developer be required to comply with an equitable access policy?
 	Should the developer be required to establish an access plan?

                    [parent] => 46
                    [count] => 49
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [pricing] => WP_Term Object
                (
                    [term_id] => 100
                    [name] => Affordable pricing
                    [slug] => pricing
                    [term_group] => 0
                    [term_taxonomy_id] => 100
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 47
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [benefit-revenue-sharing] => WP_Term Object
                (
                    [term_id] => 66
                    [name] => Benefit sharing
                    [slug] => benefit-revenue-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 66
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 14
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [business-model] => WP_Term Object
                (
                    [term_id] => 53
                    [name] => Business model
                    [slug] => business-model
                    [term_group] => 0
                    [term_taxonomy_id] => 53
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [clinical-trial-conduct] => WP_Term Object
                (
                    [term_id] => 371
                    [name] => Clinical trial conduct
                    [slug] => clinical-trial-conduct
                    [term_group] => 0
                    [term_taxonomy_id] => 371
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 12
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [confidentiality] => WP_Term Object
                (
                    [term_id] => 84
                    [name] => Confidentiality
                    [slug] => confidentiality
                    [term_group] => 0
                    [term_taxonomy_id] => 84
                    [taxonomy] => issue
                    [description] => 
 	What is the scope of confidential information?
 	What are the obligations of the parties to protect confidential information?
 	Are there any exceptions to the confidentiality obligations?
 	Are the parties permitted to make public announcements related to the project?
 	Can the parties use each other’s name and logo for general marketing materials?

                    [parent] => 49
                    [count] => 99
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [donation] => WP_Term Object
                (
                    [term_id] => 271
                    [name] => Donation
                    [slug] => donation
                    [term_group] => 0
                    [term_taxonomy_id] => 271
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 5
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [effect-of-termination] => WP_Term Object
                (
                    [term_id] => 72
                    [name] => Effects of termination
                    [slug] => effect-of-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 72
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 81
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [ensuring-continuity] => WP_Term Object
                (
                    [term_id] => 281
                    [name] => Ensuring continuity
                    [slug] => ensuring-continuity
                    [term_group] => 0
                    [term_taxonomy_id] => 281
                    [taxonomy] => issue
                    [description] => 
 	Under what circumstances can the continuity rights be exercised? (What are the conditions precedent?)
 	What is an appropriate scope for the continuity rights? What are the rights and obligations of each party?
 	Should related license grants vest upon execution of the agreement, or at a later stage in development?
 	Should there be an escrow requirement?
 	Should there be any restrictions on the developer’s ability to transfer project-related intellectual property to a third party?

                    [parent] => 46
                    [count] => 55
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [access-to-medicines] => WP_Term Object
                (
                    [term_id] => 46
                    [name] => Equitable access
                    [slug] => access-to-medicines
                    [term_group] => 0
                    [term_taxonomy_id] => 46
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [roles-responsibilities] => WP_Term Object
                (
                    [term_id] => 278
                    [name] => Governance
                    [slug] => roles-responsibilities
                    [term_group] => 0
                    [term_taxonomy_id] => 278
                    [taxonomy] => issue
                    [description] => 
 	Do the parties govern the project through a joint steering committee ("JSC")? If so, what are the parties expressly designated roles and responsibilities with respect to the JSC?
 	Are there other committees, important governance bodies, or designated individual positions? What are the parties' roles and responsibilities with respect to them?
 	Are the parties required to meet in accordance with a defined schedule for decision-making and progress reporting activities?
 	What are the resolution mechanisms for disputes related to the agreement?
 	Are there any requirements for policies or procedures to manage potential conflicts of interest?

                    [parent] => 53
                    [count] => 84
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [indemnity] => WP_Term Object
                (
                    [term_id] => 80
                    [name] => Indemnification & liability
                    [slug] => indemnity
                    [term_group] => 0
                    [term_taxonomy_id] => 80
                    [taxonomy] => issue
                    [description] => 
 	What occurrences could result in a liability claim against which one party will indemnify the other?
 	Are there any circumstances under which one party will not indemnify the other?
 	What is the process for managing liability claims?
 	Are there government or other types of indemnification schemes?
 	Is there any limitation or monetary cap on each party’s liabilities under the agreement?

                    [parent] => 50
                    [count] => 96
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [information-sharing-information-sharing] => WP_Term Object
                (
                    [term_id] => 257
                    [name] => Information sharing
                    [slug] => information-sharing-information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 257
                    [taxonomy] => issue
                    [description] => 
 	What financial and project progress information must be shared between the parties?
 	What is the required timeline for sharing information?
 	How is the receiving party permitted to use the information received?
 	Do the parties have the right to verify the information reported?

                    [parent] => 49
                    [count] => 89
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [insurance] => WP_Term Object
                (
                    [term_id] => 109
                    [name] => Insurance
                    [slug] => insurance
                    [term_group] => 0
                    [term_taxonomy_id] => 109
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 50
                    [count] => 59
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [ip-ownership] => WP_Term Object
                (
                    [term_id] => 48
                    [name] => Intellectual property
                    [slug] => ip-ownership
                    [term_group] => 0
                    [term_taxonomy_id] => 48
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [liability] => WP_Term Object
                (
                    [term_id] => 50
                    [name] => Liability
                    [slug] => liability
                    [term_group] => 0
                    [term_taxonomy_id] => 50
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [license-grants] => WP_Term Object
                (
                    [term_id] => 88
                    [name] => License grants
                    [slug] => license-grants
                    [term_group] => 0
                    [term_taxonomy_id] => 88
                    [taxonomy] => issue
                    [description] => 
 	Are any licenses granted for the use of background or foreground intellectual property?
 	What is the scope of the licensed intellectual property?
 	What is the territory of the license?
 	Is the license exclusive or non-exclusive?
 	Are there any restrictions on the use of the licensed intellectual property?
 	Are there any specific obligations to exploit the licensed intellectual property?
 	Can the licensee grant sublicenses to third parties?
 	Will products manufactured under license be marketed as branded or generic? (i.e. will they bear the licensor’s trademarks/trade dress)

                    [parent] => 48
                    [count] => 93
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [ownership-ip] => WP_Term Object
                (
                    [term_id] => 87
                    [name] => Ownership of IP
                    [slug] => ownership-ip
                    [term_group] => 0
                    [term_taxonomy_id] => 87
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 69
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [royalties-and-payments] => WP_Term Object
                (
                    [term_id] => 70
                    [name] => Payment structures
                    [slug] => royalties-and-payments
                    [term_group] => 0
                    [term_taxonomy_id] => 70
                    [taxonomy] => issue
                    [description] => What is the payment structure under this agreement? 
What are the mechanisms to limit exposure to additional payments or expenses?
                    [parent] => 53
                    [count] => 78
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [outbreak-preparedness] => WP_Term Object
                (
                    [term_id] => 102
                    [name] => Preparedness & response
                    [slug] => outbreak-preparedness
                    [term_group] => 0
                    [term_taxonomy_id] => 102
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 46
                    [count] => 12
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

            [supply-purchase-of-products] => WP_Term Object
                (
                    [term_id] => 268
                    [name] => Product supply
                    [slug] => supply-purchase-of-products
                    [term_group] => 0
                    [term_taxonomy_id] => 268
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 42
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [information-sharing] => WP_Term Object
                (
                    [term_id] => 49
                    [name] => Protecting & sharing information
                    [slug] => information-sharing
                    [term_group] => 0
                    [term_taxonomy_id] => 49
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [protection-results] => WP_Term Object
                (
                    [term_id] => 90
                    [name] => Protection of IP
                    [slug] => protection-results
                    [term_group] => 0
                    [term_taxonomy_id] => 90
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 48
                    [count] => 68
                    [filter] => raw
                    [parent_name] => Intellectual property
                    [parent_slug] => ip-ownership
                )

            [publication-of-results] => WP_Term Object
                (
                    [term_id] => 290
                    [name] => Publication of results
                    [slug] => publication-of-results
                    [term_group] => 0
                    [term_taxonomy_id] => 290
                    [taxonomy] => issue
                    [description] => What information are the parties required or permitted to publish?
What is the required timeline for making data available?
What are the acceptable publication channels?
Is compliance with a specific open access policy required?
                    [parent] => 49
                    [count] => 59
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [quality-management] => WP_Term Object
                (
                    [term_id] => 372
                    [name] => Quality management
                    [slug] => quality-management
                    [term_group] => 0
                    [term_taxonomy_id] => 372
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 35
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [regulatory-strategy] => WP_Term Object
                (
                    [term_id] => 56
                    [name] => Regulatory strategy
                    [slug] => regulatory-strategy
                    [term_group] => 0
                    [term_taxonomy_id] => 56
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 53
                    [count] => 52
                    [filter] => raw
                    [parent_name] => Business model
                    [parent_slug] => business-model
                )

            [warranties] => WP_Term Object
                (
                    [term_id] => 81
                    [name] => Representations & warranties
                    [slug] => warranties
                    [term_group] => 0
                    [term_taxonomy_id] => 81
                    [taxonomy] => issue
                    [description] => Should the parties make any warranties, and if so, what is the scope?
                    [parent] => 50
                    [count] => 84
                    [filter] => raw
                    [parent_name] => Liability
                    [parent_slug] => liability
                )

            [technology-transfer] => WP_Term Object
                (
                    [term_id] => 86
                    [name] => Technology transfer
                    [slug] => technology-transfer
                    [term_group] => 0
                    [term_taxonomy_id] => 86
                    [taxonomy] => issue
                    [description] => What is included in the technology and/or materials to be transferred?
What are the responsibilities of each party to in relation to the transfer of materials and/or technology?
                    [parent] => 49
                    [count] => 38
                    [filter] => raw
                    [parent_name] => Protecting & sharing information
                    [parent_slug] => information-sharing
                )

            [term-and-termination] => WP_Term Object
                (
                    [term_id] => 52
                    [name] => Term & termination
                    [slug] => term-and-termination
                    [term_group] => 0
                    [term_taxonomy_id] => 52
                    [taxonomy] => issue
                    [description] => Term

 	What is the term of the agreement? Is it tied to the timeline of the project or license grants?

Termination

 	Under what circumstances may a party terminate or withdraw from the agreement?

Effects of Termination

 	What are the effects of termination or withdrawal by a party?

                    [parent] => 0
                    [count] => 0
                    [filter] => raw
                    [parent_name] => 
                    [parent_slug] => 
                )

            [term-of-agreement] => WP_Term Object
                (
                    [term_id] => 76
                    [name] => Term of agreement
                    [slug] => term-of-agreement
                    [term_group] => 0
                    [term_taxonomy_id] => 76
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 83
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [termination-and-withdrawal] => WP_Term Object
                (
                    [term_id] => 74
                    [name] => Termination & withdrawal
                    [slug] => termination-and-withdrawal
                    [term_group] => 0
                    [term_taxonomy_id] => 74
                    [taxonomy] => issue
                    [description] => 
                    [parent] => 52
                    [count] => 86
                    [filter] => raw
                    [parent_name] => Term & termination
                    [parent_slug] => term-and-termination
                )

            [territory-access-commitments] => WP_Term Object
                (
                    [term_id] => 282
                    [name] => Territory access commitments
                    [slug] => territory-access-commitments
                    [term_group] => 0
                    [term_taxonomy_id] => 282
                    [taxonomy] => issue
                    [description] => 
 	How should ‘territory’ be defined under the agreement? Should the definition make a distinction between different types of purchaser (e.g. public sector vs. private sector)?
 	Should the developer be required to apply for regulatory approval in priority access markets?
 	Should the developer be required to commit a proportion of the product manufactured to a certain country or purchasing organization?
 	Should the developer be required to identify a third party that could fulfill supply requirements for the access territories in the event that the developer does not?
 	Should the agreement include any anti-diversion provisions?

                    [parent] => 46
                    [count] => 55
                    [filter] => raw
                    [parent_name] => Equitable access
                    [parent_slug] => access-to-medicines
                )

        )

    [filter_issues:GHIAA2019\MapguideSearch:private] => Array
        (
        )

)